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Abstract
EFSA received a mandate from the European Commission to assess the effectiveness of some of the
control measures against diseases included in the Category A list according to Regulation (EU) 2016/
429 on transmissible animal diseases (‘Animal Health Law’). This opinion belongs to a series of
opinions where these control measures will be assessed, with this opinion covering the assessment
of control measures for foot and mouth disease (FMD). In this opinion, EFSA and the AHAW Panel of
experts review the effectiveness of: i) clinical and laboratory sampling procedures, ii) monitoring period
and iii) the minimum radius of the protection and surveillance zones, and the minimum length of time
the measures should be applied in these zones. The general methodology used for this series of
opinions has been published elsewhere; nonetheless, the transmission kernels used for the assessment
of the minimum radius of the protection zone of 3 km and of the surveillance zone of 10 km are
shown. Several scenarios for which these control measures had to be assessed were designed and
agreed prior to the start of the assessment. The monitoring period of 21 days was assessed as
effective, and it was concluded that the protection and the surveillance zones comprise > 99% of the
infections from an affected establishment if transmission occurred. Recommendations, provided for
each of the scenarios assessed, aim to support the European Commission in the drafting of further
pieces of legislation, as well as for plausible ad hoc requests in relation to FMD.
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Summary
This opinion is part of a series of opinions, in which the three first terms of reference (ToRs) of a
mandate received from the European Commission have been considered. The background and specific
details of this mandate can be found in the opinion. The ToRs in this mandate request an assessment
of the effectiveness of:
• the clinical and laboratory examination in their capacity to detect disease (or estimate the
disease prevalence within an establishment), either in suspect or confirmed animals in a single
establishment, or in establishments within restriction zones (ToR 1);
• the effectiveness of the duration of the monitoring period (for different scenarios) in the control
of suspected and confirmed outbreaks (ToR 2);
• the size and duration of the restriction zones, in their capacity for mitigating disease spread
(ToR 3).
In order to harmonise the approach to these assessments, the methodology used in this series of
opinions, covering all Category A diseases, was agreed on and published in a separate technical report.
Specific clinical and laboratory procedures for foot and mouth disease (FMD) for each scenario of
ToR 1 have not been found in the EU legislation. Specific sampling procedures for clinical and
laboratory examination have been provided for some scenarios.
To answer ToR 2, and to assess the minimum length of time measures should be implemented in
the protection and surveillance zones (ToR 3.2), an extensive literature search (ELS) was carried out.
This ELS aimed to assess the average, shortest and longest period between the earliest point of
infection of cattle with FMD virus and the time of reporting of a suspicion by the competent authority.
The average time to the reporting of a suspicion was then used to assess the effectiveness of the
length of monitoring periods. For most of the scenarios, the existing length of the monitoring period
for FMD (21 days) was considered sufficient. Recommendations were given for some of the relevant
scenarios. To assess the effectiveness of the minimum length of time in which the measures should be
applied in the protection and surveillance zones, the average and the longest time assessed via the
ELS were used, respectively. In this regard, the minimum length of time of the protection zone
(15 days) and the surveillance zone (30 days) that must be in place according to existing legislation
were considered effective.
To assess the effectiveness of the minimum radius to be implemented in the protection and
surveillance zones (ToR 3.1), transmission kernels were used. These kernels had been built using data
from previous outbreaks in the Netherlands, Japan and United Kingdom. These kernels represent the
relative risk of transmission to each individual establishment from the affected establishment. For FMD,
it was observed that, assuming transmission from an affected establishment occurs, the median
probability of transmission beyond the protection zone of 3 km was 4.8%. The median probability of
infection of an establishment located beyond 10 km was 0.3%. Nevertheless, transmission to longer
distances cannot be excluded if infected animals are moved outside the zones.
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1. Introduction
1.1. Background and Terms of Reference as provided by the requestor
Regulation (EU) 2016/429 on transmissible animal diseases (‘Animal Health Law’), hereinafter
referred to as AHL, requires the Commission to lay down detailed rules on the disease control measures
against listed diseases as referred to in point (a), (b) and (c) of its Article 9 (Category A, B and C
diseases). The Commission is empowered to adopt delegated acts supplementing the rules laid down in
Part III of Regulation (EU) 2016/429 on transmissible animal diseases (Animal Health Law) on disease
control measures for listed diseases as referred to in point (a), (b) and (c) of its Article 9 (Category A, B
and C diseases). Therefore, the Commission has developed and adopted a Delegated Regulation laying
down rules for the prevention and control of certain diseases (‘the Delegated Regulation’). The rules laid
down in the Delegated Regulation are in respect of terrestrial animals largely replicating the rules
currently in force concerning the disease control measures in the event of animal diseases with serious
effects on the livestock as they have proven to be effective in preventing the spread of those diseases
within the Union. Consequently, many animal disease control measures laid down in existing Directives
will be, to the extent that not already done by the Animal Health Law, replaced by the rules provided in
the Delegated Regulation. At the same time, these rules have been aligned with the international
standards from the World Organisation for Animal Health (OIE), wherever these existed. However,
certain disease control measures proposed in the Delegated Regulation, in particular in its Annexes, were
considered as outdated i.e. possibly not based on most recent scientific evidence at the time of
development. Their review is considered as necessary. Moreover, for those Category A diseases for which
rules were not established before or were not detailed enough, certain disease control and risk
mitigating measures are, due to the lack of scientific basis, extrapolated from other diseases, for which
rules existed in the past. Finally, for some other diseases the evidence and scientific knowledge, was not
available to the Commission and to the Member States at the time of developing the Delegated
Regulation due to the time constraints. The following diseases are examples of the later: infection with
Rift Valley fever (RVF), infection with Mycoplasma mycoides subsp. mycoides SC (Contagious bovine
pleuropneumonia) (CBPP), Contagious caprine pleuropneumonia (CCPP), Sheep pox and goat pox,
infection with peste des petits ruminants virus (PPR), African horse sickness (AHS), Glanders. In this
regard, the existing rules will cease to apply as from the date of application of the Animal Health Law and
its complementing legislation including the Delegated Regulation, i.e. from 21 April 2021. Certain of the
proposed measures for the prevention and control of Category A diseases of terrestrial animals should
therefore be assessed in order to ensure that they are effective and updated based on the latest
scientific knowledge in this new set of legislation. This is particularly important in the case of those
diseases that are less common or have been never reported in the Union.
1.1.1. ToR 1: Sampling of animals and establishments for the detection of
Category A diseases in terrestrial animals
Based on available scientific information, assess the effectiveness of existing sampling procedures
to detect or rule out the presence of each Category A disease of terrestrial animals and, in case of
absence of effective procedures, develop them, in order to complete the rules provided for in Annex I
to the Delegated Regulation. In particular, provide for disease-specific procedures for the sampling of:
ToR 1.1 Animals for clinical examinations to ensure the detection of the relevant Category A disease
during the performance of official investigations in establishments that are affected or suspected to be
affected by Category A diseases and visits in establishments located in restricted zones in accordance
with Articles 6(2), 13(3)(c), 14(1) and 26(2) of the Delegated Regulation.
ToR 1.2 Animals for laboratory examinations to ensure the detection of the relevant Category A
disease during the performance of official investigations in establishments that are affected or
suspected to be affected by Category A diseases and visits in establishments located in restricted
zones in accordance with Articles 6(2), 12(3), 13(3)(c), 14(1), 26(2) of the Delegated Regulation.
ToR 1.3 Establishments to ensure the detection of the relevant Category A disease for the
performance of visits in establishments located in protection zones larger than 3 km and
establishments located in the surveillance zone in accordance with Articles 26(5) and 41 of the
Delegated Regulation.
ToR 1.4 Animals for clinical and laboratory examinations to ensure the detection of the relevant
category A disease for the movement of animals from restricted zones in accordance with Articles 28
(5), 43(5), 56(1)(c) of the Delegated Regulation.
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ToR 1.5 Animals for laboratory examinations to ensure the detection of the relevant Category A
disease before and after being introduced in the affected for repopulation, in accordance with Article
59(2), (3) and (9) of the Delegated Regulation.
1.1.2. ToR 2: Monitoring period
ToR 2.1 Assess the effectiveness of the length of the monitoring periods set out in Annex II of the
Delegated Regulation for each Category A disease of terrestrial animals. In this regard, it is important
to take into consideration that the monitoring period was introduced as a management tool, which
represents a time frame of reference assigned to each Category A disease for the competent authority
to apply certain control measures and to carry out investigations in the event of suspicion and
confirmation of Category A diseases in terrestrial animals.
This assessment should be carried out with respect to the following situations:
a) the records analysis carried out by the competent authority in the framework of the
epidemiological enquiry referred to in Article 57 of Regulation (EU) 2016/429, in the event of
suspicion of a category A disease (Article 8(4) of the Delegated Regulation);
b) the derogation from killing in the event of an outbreak of a Category A disease in
establishments keeping animals of listed species in two or more epidemiological units (Article
13(1) of the Delegated Regulation);
c) the tracing carried out by the competent authority to identify establishments and other
locations epidemiologically linked to an establishment affected by a Category A disease
(Article 17(2) of the Delegated Regulation);
d) the exemption applied to certain products from the prohibitions laid down in Annex VI taking
into account the date they were produced (Article 27(3)(c) of the Delegated Regulation);
e) the specific conditions for authorising movements of semen from approved germinal product
establishments in the protection and surveillance zones (Article 32(c) and 48(c) of the
Delegated Regulation);
f) the repopulation of establishments affected by a Category A disease (Article 57(1)(b) and 59
(4)(b) of the Delegated Regulation).
ToR 2.2 Propose the length of what should be the monitoring period in those diseases for which
the time is assessed as not effective.
1.1.3. ToR 3: Minimum radius of restricted zones and duration of the disease
control measures in restricted zones
ToR 3.1 Assess the effectiveness to control the spread of the disease of the minimum radius of the
protection and surveillance zones set out in Annex V of the Delegated Regulation for each Category A
disease of terrestrial animals.
ToR 3.2 Assess the effectiveness to control the spread of the disease of the minimum periods
during which the competent authority should apply the restriction measures in the protection and
surveillance zones as set out in Annexes X and XI for each Category A disease of terrestrial animals.
1.1.4. ToR 4: Prohibitions in restricted zones and risk-mitigating treatments for
products of animal origin and other materials
ToR 4.1 Assess the effectiveness to control the spread of disease of prohibitions set out in Annex VI
of the Delegated Regulation with respect to the risk associated for each category A disease, to the
listed activities and commodities.
ToR 4.2 Review the available scientific information on risk-mitigating treatments that are effective to
control the presence of category A disease agents in products of animal origin and other relevant
materials. Based on this:
• provide an opinion on the effectiveness of the risk-mitigating treatments for products of animal
origin and other materials produced or processed in the restricted zone set out in Annex VII
and VIII, and
• if relevant, suggest new treatments or procedures that can be effective to mitigate or to
eliminate such risk
Control measures of Foot and Mouth Disease
www.efsa.europa.eu/efsajournal 7 EFSA Journal 2021;19(6):6632
1.2. Interpretation of the Terms of Reference
To address the ToRs of the mandate, EFSA proposed and agreed with the European Commission
the following:
a) The publication of 14 individual opinions, one per each of the diseases included in the list of
Category A diseases for terrestrial animals, with each of these opinions providing the answer
to ToRs 1, 2 and 3. The current manuscript is one of the 14 opinions covering ToRs 1, 2 and
3 for foot and mouth disease (FMD).
b) The publication of a unique opinion covering ToR 4 for all diseases listed (i.e. ToR 4 is not
covered in this opinion).
c) To address ToR 1 (effectiveness of sampling procedures), EFSA agreed with the European
Commission on 21 scenarios based on different articles of the Delegated Regulation (EC) 2020/
687 (hereinafter referred to as Delegated Regulation), for which the effectiveness of the sampling
procedures will be assessed (Annex B). Although these scenarios will be assessed independently,
some of these scenarios may be merged if the assessment processes are the same.
d) To address ToR 2 (effectiveness of the monitoring period), seven scenarios previously agreed
with the contractor were defined (Annex D). The assessment of the effectiveness of the
monitoring period will be done by assessing its ability to ensure that specific actions can be
carried out without posing a risk of disease spread, if the monitoring period is calculated
backwards or forwards from a specific date. If the length of the monitoring period estimated
by EFSA is longer than the existing monitoring periods, the existing monitoring period will be
considered non-effective. If the length of the monitoring period estimated by EFSA is shorter
than the existing monitoring period, this existing monitoring period will be considered effective
from a disease control point of view. No assessment of the plausible unnecessary economic
burden that may be placed on the stakeholders as a result of an excessive length of the
monitoring periods will be done by EFSA.
e) The assessment of the minimum duration and the length of the radius of the protection and
surveillance zones (ToR 3) will be done independently. The setting of these two zones
(protection and surveillance zones) surrounding an affected establishment and the control
measures implemented in each one of the zones are based on the general principle that the
probability of disease spread is larger the closer the establishment is to an affected
establishment. The validity of this statement will not be assessed in this manuscript;
nonetheless, the limitations that this assumption may have in the control of certain diseases
will, when relevant, be discussed.
f) The following scenarios of the ToR 1 of Annex B are not relevant for the FMD, and therefore
not included in the assessment of the current Opinion:
i) scenario 7 because the minimum radius of the protection zone for FMD is 3 km,
ii) scenarios 10, 11, 16 and 17 because they are referring to poultry.
g) The duration of the monitoring period for FMD as described in Annex II of the Delegated
Regulation is 15 days.
h) The minimum length of the radius of the protection zone and surveillance zone for FMD as
described in Annex V of the Delegated regulation are 3 and 10 km, respectively.
i) The minimum duration of the measures in the protection and surveillance zone for FMD as
described in Annexes X and XI of the Delegated Regulation is 30 days for both zones.
2. Epidemiology and geographical distribution of FMD virus
2.1. Epidemiology
Aetiology
Foot and mouth disease is a highly contagious, usually non-fatal vesicular disease affecting mostly
domestic and wild cloven-hoofed animals (of the order of the Artiodactyla). The causative agent is the
FMD virus (FMDV), a non-enveloped RNA virus, member of the genus Aphthovirus in the family
Picornaviridae, existing in seven distinct serotypes: O, A, C, SAT 1, SAT 2, SAT 3 and Asia 1 (Leforban,
2003; OIE, 2013, 2019; Spickler, 2015).
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Epidemiology
FMDV can infect important livestock species such as pigs, cattle, sheep and goats, water buffalos
and yaks. Bactrian camels are susceptible unlike dromedary camels; alpacas and llamas may be
infected, but do not play a role in transmission (Fondevila et al., 1995). More than 70 wild ungulate
species are susceptible including cervids, bison, European wild boar, warthog, antelopes and gazelles,
giraffe and African buffalo, the latter being considered a major reservoir for FMDV in Africa, especially
for the SAT serotypes (Leforban, 2003; Spickler, 2015). A few species not belonging to the Artiodactyla
order can also be infected (e.g. elephant, hedgehog, bear, kangaroo, capybara, nutrias) (Spickler,
2015). Apart from African buffalo, wildlife does not seem to be able to maintain FMDV infection for
long periods (Spickler, 2015; Elnekave et al., 2016), but could play a role in virus transmission to
livestock in some circumstances (Elnekave et al., 2016).
Despite the fact that mortality is usually low in adult livestock, FMD is a notifiable disease due to its
high contagiousness, high morbidity and impact on animal welfare. It is responsible for severe
economic losses in production animals and for disruption in national and international trade due to
livestock and livestock products movement restrictions from affected countries or regions to disease-
free areas (Leforban, 2003).
The disease can be transmitted directly via the respiratory route (aerosol) or by contact with fluids
such as saliva, faeces, urine, milk and semen from infected animals. Indirect transmission can occur
through fomites (vehicles, equipment) humans, ingestion of contaminated feed (especially in pigs) or
via airborne spread. Pigs are less susceptible to aerosol infection than cattle, yet they excrete far more
aerosolised virus than cattle or sheep (Grubman and Baxt, 2004).
Animals that have recovered or have been vaccinated and subsequently exposed can experience
persistence of FMDV in the oropharynx for more than 28 days and are defined as virus carriers. The
duration of this status depends on the species: usually 6 months or less in cattle (up to 3.5 years), 1–5
months in sheep (up to 12 months), up to 4 months in goats and up to 1 year in water buffalo
(Spickler, 2015). It is believed that FMDV carriers do not play a major role in the epidemiology of the
disease, except for African buffalo, which can shed the virus for at least 5 years (Leforban, 2003;
Grubman and Baxt, 2004; Dekker et al., 2008; Spickler, 2015).
The control of the disease depends on the FMD status and the legislation and policy of the affected
countries. In endemic zones, inactivated vaccines are used, but they need to match the circulating
strains since there is no cross-protection immunity between serotypes and cross-protection might be
limited between different strains of the same serotype. In FMD-free regions such as in the EU,
vaccination is not routinely used and is restricted to outbreak control (ring vaccination). In case of re-
emergence of the disease, measures such as active and passive surveillance, contact tracing, strict
livestock movement restrictions and stamping out (culling) of susceptible animals in infected premises
are implemented to avoid the spread of the virus (Leforban, 2003; Grubman and Baxt, 2004; Spickler,
2015).
Clinical signs and diagnosis
The incubation period is 2–14 days in cattle and small ruminants, and usually shorter in pigs (1–2
days). Typical clinical signs are fever, depression and drop in milk production in dairy animals, followed
within 24 h by the eruption of multiple vesicles localised on the feet (interdigital space, hooves),
muzzle, mouth (tongue and gums) and udder. Vesicles rapidly rupture and become ulcers causing pain,
anorexia, hypersalivation, drooling, lameness and reluctance to walk (Geering and Lubroth, 2002;
Leforban, 2003; Grubman and Baxt, 2004; Spickler, 2015). Determining the age of FMD lesions,
especially when the disease is first recognised in a herd/flock, is a useful aid to estimate the
approximate time of first infection (Geering and Lubroth, 2002).
Morbidity can reach 100% in naive cattle or pigs, especially in highly productive breeds, but
depends on the strain virulence and on the affected species, with cattle and pigs being more severely
affected than small ruminants, which frequently present mild or asymptomatic forms. Mortality is
usually low in adult animals (1–5%), recovering within 1–3 weeks, sometimes with sequelae (chronic
lameness, decrease in milk production). In contrast, mortality is higher (up to 50% or more) in very
young animals (calves, piglets, lambs), which can die from myocarditis or anorexia (Leforban, 2003;
Spickler, 2015).
Detection of FMDV during the acute phase of the disease is routinely performed with antigen
capture ELISAs or with RT-PCR (gel based or real time, the latter being highly sensitive), using samples
such as vesicular fluids, epithelial tissue from fresh vesicles, blood serum or oesophageal–pharyngeal
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(OP) fluids (collected with a probang cup in ruminants or throat swabs in pigs). Commercial lateral flow
device tests performed on epithelial suspension are useful at field level to confirm clinical cases once the
disease is present in a region (Grubman and Baxt, 2004; Spickler, 2015; OIE, 2019).
Seroconversion occurs 1–2 weeks after infection and can be detected using serological tests such
as virus neutralisation tests and ELISAs that detect antibodies to viral structural proteins and are
serotype specific but cannot differentiate infected from vaccinated animals (DIVA). In contrast, non-
structural proteins (NSP) are only produced during viral replication, inducing antibodies in infected but
not in vaccinated animals, which will test negative in NSP ELISAs, provided that the vaccine used is
sufficiently purified. DIVA tests allow the use of targeted vaccination to control outbreaks in FMDV-free
countries, with the possibility to regain their FMDV-free status without necessarily slaughtering
vaccinated but uninfected animals, though this strategy has never been implemented in the EU so far
(Leforban, 2003; Grubman and Baxt, 2004; Paton et al., 2014; Spickler, 2015; OIE, 2019).
2.2. Geographical distribution of foot and mouth disease
FMD has been eradicated from North America, Australasia, Europe and much of South America
(Figure 1) by zoosanitary measures supported in some cases by vaccination campaigns. FMD is still
widespread throughout the rest of the world, particularly in Asia, Africa and the Middle East (Figure 2).
On average, more than 100 countries are not FMD-free. The FMD situation in Venezuela is of particular
concern to South America. Over the last 10 years, new FMD strains belonging to different serotypes
have been spread from Indian subcontinent while SAT strains from Southern Africa escaped into North
Africa and Middle East (EuFMD, 2020b).
The spread of new FMDV strains in the last decade into Turkey, the Middle East and North Africa
raises concerns and warrants increased awareness in Europe mainly for two reasons: i) these new and
more frequent introductions show that new pathways (trade, migration) bringing new FMDVs have
been established and ii) the vaccines in the EU vaccine bank may have a poor match with these new
strains, and therefore, there may be a need to develop new vaccines.
Figure 1: Map of countries or zones with the OIE official free status for Foot and mouth disease,
2020 (Source: OIE, © OIE)
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3. Data and methodologies
3.1. Methodologies
3.1.1. Methodology used in ToR 1
A qualitative assessment of the clinical and laboratory procedures was performed to answer ToR 1.
Estimation of sample size, when needed, was carried out using the RiBESS+ tool.1
To answer the first scenario of ToR 1 in the event of FMD suspicion in an establishment, some
additional calculations were needed.
The positive predictive value of the clinical examination (PPVclinical, the probability that a selected
animal clinically classified as positive is truly FMDV infected) at a certain design prevalence is given by
the following equation:
PPVclinical ¼ P(true positive)P(true positive) + P(false positive) ¼
Seclinical  DP
Seclinical  DPþ ð1 DPÞ  ð1 SpclinicalÞ
(1)
where Seclinical is the sensitivity of the clinical examination, DP is the design prevalence that needs to
be detected and Spclinical is the specificity of the clinical examination.
The overall probability to detect FMDV by a laboratory test (PCR or Ag ELISA) with a single skin
sample would be
Pdetect ¼ PPVclinical  Selabtest (2)
where Selabtest is the sensitivity of the laboratory test used.
Figure 2: Map of countries with notified outbreaks of foot and mouth disease in 2015–2020 (Data
sources: ADNS and OIE)
1 RiBESS+ tool https://efsa.openanalytics.eu/app/ribess
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The probability that at least one truly infected animal is detected is given by the equation:
Seoverall ¼ 1 ½ð1 PdetectÞn (3)
Based on the Seoverall to be achieved, the n (number of samples needed to be collected) can be
calculated
n ffi ln(1 SeoverallÞ
ln(1 PdetectÞ
: (4)
3.1.2. Methodology used in ToR 2
To answer ToR 2, an extensive literature search (ELS) was outsourced by EFSA (OC/EFSA/ALPHA/
2020/02 - LOT 2). The aim of this ELS was to answer the epidemiological question: what is the
average, shortest and longest period of time (measured as the number of days from the earliest point
of infection with FMDV to the time of declaration of a suspicion by the competent authority after the
clinical investigation by an official veterinarian) for an outbreak of FMD to be reported. To answer this
question, an ELS on case reports, papers describing outbreaks or epidemics of FMD and any other
relevant grey literature or data was carried out. For the inclusion criteria in the ELS, the earliest point
of infection had to have been estimated by carrying out an epidemiological investigation. Papers and
other sources of data were excluded when the earliest point of infection was determined purely by
subtracting a known incubation period from the date of the suspicion of the outbreak. The ELS was
restricted to studies conducted in Europe or describing results obtained in Europe. If none or very few
articles were retrieved (less or equal to 5) in the first search, the search was extended to the rest of
the world. The general protocol used for the ELS is shown in Annex 5 of the Technical report (EFSA,
2020).
3.1.3. Methodology used in ToR 3
Methodology for assessing the effectiveness of the minimum radius of the protection and
surveillance zones
Studies investigating the transmission of FMDV between establishments using transmission kernels
were identified in the published literature. The functional form, parameter estimates and the 95%
confidence or credible intervals for the parameters of the best-fitting kernel were extracted from each
study (where provided).
For each kernel, the probability of transmission beyond given distances (if transmission were to
occur from an affected establishment) was computed using the estimates and the lower and upper
95% confidence limits for the parameters. In addition, the distances at which a given threshold
probability of transmission beyond that distance is reached were also calculated for each kernel using
the estimates along with its lower and upper 95% confidence limits. More details are provided in the
Technical report (EFSA, 2020).
Methodology for assessing the effectiveness of the duration of the protection and
surveillance zones
To estimate the duration of measures in the protection and surveillance zones, the outputs
obtained from the ELS described in Section 4.2.1 were used. Further details can be found in the
Technical report (EFSA, 2020).
3.1.4. Uncertainty
A description of the methodology followed to deal with uncertainty is provided in a Methodology
report published by EFSA (EFSA, 2020).
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4. Assessment
4.1. Assessment of sampling procedures
4.1.1. Assessment of sampling procedures in the event of suspicion or
confirmation of Foot and mouth disease (FMD)
4.1.1.1. In the event of a suspicion of FMD in kept animals of listed species in an
establishment
The purpose of this section is to assess the effectiveness of disease-specific sampling procedures of
animals of listed species in a suspected establishment, based on clinical examination (ToR 1.1) and
laboratory examination (ToR 1.2), in their ability to detect FMD in kept animals if the disease is present in
that establishment, or to rule it out if not present (Art. 6 (2)). For further details, see Annexes B and C.
Summary of sampling procedures
1. Clinical examination: Council Directive 2003/85/EC: Annex III:
‘1.1. Holdings must undergo clinical examinations of all animals of susceptible species for signs or
symptoms of foot-and-mouth-disease.
1.2. Special emphasis must be laid to animals that may have been exposed to foot-and-mouth
disease virus with a high probability, notably transport from holdings at risk or close contact to persons
or equipment that had close contact to holdings at risk.
1.3. The clinical examinationmust take into account the transmission of foot-and-mouth-disease, including
the incubation period referred to in Article 2(h) and theway in which animals of susceptible species are kept.
1.4. Relevant records kept on the holding must be examined in detail with particular regard to data
required for animal health purposes by Community legislation and, where available, on morbidity,
mortality and abortion, clinical observations, changes in productivity and feed intake, purchase or sale
of animals, visits of persons likely to be contaminated and other anamnestically important information.
2. Laboratory examination: Council Directive 2003/85/EC: Annex III 2.2.: Sampling on holdings: In
holdings where the presence of foot-and-mouth-disease is suspected, but in the absence of clinical
signs, sheep and goats, and on recommendation of the epidemiological team other susceptible
species, should be examined pursuant to a sampling protocol suitable to detect 5% prevalence with at
least 95% level of confidence.’
Assessment
In the scenario of a suspicion of FMD in an establishment, the purpose of the clinical examination2
(including both the initial visual inspection of the herd and the individual examination of the animals) is
to identify the cases and collect samples for further laboratory analysis.
• 1st scenario of sampling procedures
• ToR 1.1 and ToR 1.2 in accordance with Article 6(2) of the Delegated Regulation (EU) 2020/687
• Commission Implemented Regulation 2018/1882 on listed species
The following elements of the scenario should be taken into consideration for the assessment:
1) It concerns an event of suspicion of FMD in an establishment of kept animals of listed species for
FMD;
2) The listed species for FMD as provided in Commission Implemented Regulation 2018/1882 belong to:
Artiodactyla and Proboscidea;
3) In the event of a suspicion of FMD, the competent authority shall immediately conduct an
investigation to confirm or rule out the presence of the FMD;
4) On the day of the investigation, the official veterinarians must perform clinical examinations and
collect samples for laboratory examinations.
2 Definition of the term ‘clinical examination’ is provided in the article 3 of the Delegated Regulation: the clinical examination
comprises: i) an initial general evaluation of the animal health status of the establishment which comprises all the animals of listed
species kept in the establishment; and ii) an individual examination of the animals included in the sample referred to in point (a).
The sampling of animals for clinical examination is carried out in accordance with point A.1 of Annex I for terrestrial animals.
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FMD is of variable severity between species, with dairy cattle and pigs showing obvious signs of
illness, whilst infection can be mild or subclinical, especially in small ruminants and partially immune
animals (Paton et al., 2014). The clinical signs of FMD are quite specific and suspicion of the disease
can be raised when only one animal in a herd is infected (Bouma et al., 2003).
Early detection of FMD in an establishment, when only one or a few animals have been infected, is
highly preferred as in such a situation the probability that the infection has spread beyond this
affected establishment is still low. Therefore, the minimum number of animals to be examined
proposed here allows the detection of the clinical signs’ indicative for FMD at the design prevalence of
2% with 95% confidence level.
Regarding the specificity of clinical examination, there are no data from the literature, but it cannot
be considered 100% as some clinical signs may be confused with other diseases e.g. mucosal disease
and certain manifestations of bluetongue or malignant catarrhal fever in cattle or contagious ecthyma
and foot rot in sheep and goats, swine vesicular disease in pigs. Consequently, in a establishment
where one of these diseases would be present in addition to FMD, selecting only a single animal for
laboratory testing could result in missing the diagnosis of FMD. For the purposes of this opinion, we
assume the specificity of clinical examination to detect FMDV infected animals with clinical signs to be
99%. This implies that one in 100 animals not infected with FMD would be considered clinically
suspect, because of diseases in the differential diagnosis.
In case of a suspicion of FMD in cattle or a pig herd in naive populations, the sensitivity of the
clinical examination to detect animals with clinical signs could be considered high for this scenario. The
reason is that the visit is the result of a suspicion raised by the keeper or veterinarian. However, no
estimates for the sensitivity of clinical examination in naive populations have been published. In
experimental settings, the sensitivity of clinical diagnosis of contact infected animals was 100% (Eble
et al., 2006; Orsel et al., 2007). Nevertheless, for this assessment, we assume that it to be lower in
practice, because of less ideal circumstances in an establishment compared to a controlled experiment.
For that reason, we used a sensitivity of 90% in this assessment. While in populations where the
disease is endemic or in sheep and goat herds, the sensitivity is much lower and a sensitivity of 30%
was used according to an estimate of Gonzales et al. (2014) in partially immune cattle populations.
PCR and virus isolation can be used to examine epithelium, mouth swabs or oropharyngeal (OP)
samples, milk and serum/blood. ELISA, complement fixation (CF) and the lateral flow device are suited
to the examination of epithelial suspensions or vesicular fluids but are insufficiently sensitive for the
direct examination of OP samples or serum/blood.
Nevertheless, the collection of the OP fluid is not very easy in practice, as it requires a very specific
tool (the probang cup), the sample should be stored at 70Co and can be tested only by virus
isolation and RT-PCR. Recovery of virus or viral genome can be irregular and one reason for this could
be the difficulty in obtaining a consistent sample of mucus and epithelium by means of a probang
sampling cup (Parida et al., 2005). Parida et al. (2005) found more samples positive by RT-PCR than
by virus isolation, particularly at the later post infection time points. Paton et al. (2006) mentioned that
probang sampling followed by RT-PCR had a sensitivity of 50% for detecting FMDV genome in
persistently infected animals without clinical signs.
The EFSA Opinion on FMD (EFSA AHAW Panel, 2006) mentions that exact figures for the sensitivity
(Se) and specificity (Sp) of the laboratory methods for FMDV are hardly or never found in the
literature. The following Table 1 presents the sensitivity and the specificity of some laboratory assays
based on the review of several scientific articles.
Table 1: Sensitivity and specificity of different laboratory methods, in different sample matrices
Sample
matrices
Method of analysis Sensitivity (Se) Specificity (Sp)
Agent identification
Epithelium 3D rRT-PCR 97.7%(1) Not available
50UTR rRT-PCR 95.4%(1) 100%(2)
3D and 50UTR rRT-PCR* 99.5%(1) Not available
Serum 3D rRT-PCR 98.8% (95% CI: 93.47–99.97)(3) 100% (95% CI: 94.04–100)(3)
50UTR rRT-PCR 100% (95% CI: 95.65–100)(3) 100% (95% CI: 94.04–100)(3)
Swabs 3D rRT-PCR Not available 100%(4)
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Development of new procedures
Clinical Examination
The individual clinical examination should focus primarily on those animals identified by the owner/
farmer as suspects for FMD or identified by the veterinarians based on clinical signs resembling FMD
during the initial visual inspection of the herd (targeted sampling). Animals showing excess salivation,
anorexia, lameness, milk drop, reluctance to move and those that are remaining isolated and
separated from the herd should be examined carefully for vesicular lesions. Cattle may ‘chomb’ and
grind their teeth. In sheep and goat herds, lameness may be the only symptom at acute stages of the
disease.
Appropriate samples for the laboratory analyses must be collected from animals exhibiting clinical
signs typical for FMD and sent immediately to the laboratory.
The aim of clinical extermination in this scenario is to detect a sufficient number of animals with
clinical signs and collect the minimum number of samples for laboratory examination (see below
Table 4). If the number of animals (or more) shown in Table 4 for the laboratory analysis has been
already identified, clinical inspection of the whole herd is not needed. On the other hand, if only one or
a few suspected animals are identified, further animals should be examined. In that case, the
minimum number of animals to be clinically examined to identify animals with clinical signs at a 95%
confidence level should be selected according to Table 2 and Figure 3.
From the results in Table 2 and Figure 3, it can be seen that detecting animals with clinical signs
with 95% confidence, when assuming only one or a few infected animals (2% in larger populations),
cannot be achieved in herd sizes < 100, even if the sensitivity of clinical examination is high (90%);
this is the case in naive cattle and pig populations even if all animals are clinically inspected. For herds
sizes > 100, the number of animals to be inspected should be as per Table 2. When the herd
sensitivity is low (30%), as it is the case in naive sheep and goat populations, vaccinated animals and
animals in endemic areas (if such scenario ever arises in the European Union), achieving 95%
Sample
matrices




Mab Ag-ELISA 79%(5) 100%(5)
Polyclonal Ab Ag-ELISA 72%(5) 100%(5)









Vaccinated cattle exposed to
infection (28–100 dpi):(7)
99.2%(7)
SPC-ELISA 100% 21 dpi or dpv:(8) Cattle 99.44%; sheep 99.50%;
pig 100%(9)
VNT 95–97%(9),(10) 99–100%(9),(10)
rRT-PCR: real-time Reverse Transcription Polymerase Chain Reaction; SPC: Solid-phase competitive.
*: Performing 3D rRT-PCR and 50UTR rRT-PCR in parallel (Combined PCR).
(1): King et al. (2006).
(2): Reid et al. (2002).
(3): Vandenbussche et al. (2017).
(4): Paix~ao et al. (2008).
(5): Grazioli et al. (2020).
(6): Roeder and Le Blanc Smith (1987).
(7): Brocchi et al. (2006).
(8): Mackay et al. (2001).
(9): Paiba et al. (2004).
(10): Lefebvre D., Sciensano3, test validation dossier, personal communication.
3 European Reference Laboratory for FMD.
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confidence is not possible for herds below 500 animals. Even then, most animals in the herd would
have to be inspected (Table 2).
In Table 2, the design prevalence had to be adjusted for herd sizes ≤ 50 to reflect the assumption
of at least one animal presenting clinical signs. The samples in both examples have been collected
from all the various groups of animals present in the establishment.
In the graphs of Figure 3 and in Table 2, we can see that confidence level of 95% to detect
animals with clinical signs, assuming a design prevalence of 2%, cannot be achieved even if all the
animals in the herd were sampled, especially when the sensitivity of clinical examination is low. On the
other hand, higher values of sensitivity in clinical examination decrease the sample size needed to
reach the 95% confidence level with the same design prevalence of 2%.
Table 2: Sample size and confidence level (probability to detect animals with clinical signs) achieved
in an establishment as a function of the herd size, assuming a target (design) prevalence
of animals with clinical signs of 2%, and using two different values of the sensitivity of the
clinical examination Se = 90% and Se = 30%
Herd
size (n)
Examples for Sensitivity of the clinical
examination Se = 90% (e.g. naive cattle
and pig populations)
Examples for Sensitivity of the clinical
examination Se = 30% (e.g. naive sheep
and goat populations, vaccinated animals,















10 10%* 10 89% 10%* 10 –
20 5%* 20 89% 5%* 20 –
50 2% 50 90% 2% 50 30%
100 2% 86 95% 2% 100 50%
200 2% 117 95% 2% 200 76%
250 2% 125 95% 2% 250 83%
300 2% 131 95% 2% 300 88%
500 2% 143 95% 2% 431 95%
750 2% 150 95% 2% 452 95%
1000 2% 154 95% 2% 463 95%
*: The minimum number of animals with clinical signs in a herd is one. Therefore, the values provided here for the design
prevalence are the result of the ratio between 1 and the herd size.
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The confidence to detect animals with clinical signs using clinical examination can be improved by
increasing the: i) sensitivity of the clinical examination (e.g. through use of well-trained veterinarians
performing a thorough individual clinical examination), and ii) number of animals to be tested
(preferably all the animals in the establishment).
Laboratory Examination
For the laboratory diagnosis of FMD, the tissue of choice is epithelium from unruptured or freshly
ruptured vesicles or vesicular fluid (Geering and Lubroth, 2002; OIE, 2019). Ideally, at least 1 g or
1–2 cm2 of epithelial tissue should be collected from an unruptured or recently ruptured vesicle,
usually from the tongue, buccal mucosa, feet or udder (Geering and Lubroth, 2002; OIE, 2019). Other
samples that can be taken to detect the presence of the virus are EDTA-blood, serum and milk
(Armson et al., 2018; OIE, 2019). From fatal cases, myocardial tissue or blood can be collected, but
epithelium of vesicles are again preferable if present (OIE, 2019).
OIE and several publications proposed that wherever epithelial tissue is not available, for example
in advanced or convalescent cases, or where infection is suspected in the absence of clinical signs,
samples of mouth swabs can be collected from all species or OP fluid in ruminants, by means of a
probang (sputum) cup or in pigs by swabbing the throat, for submission to a laboratory for virus
isolation or reverse-transcription polymerase chain reaction (RT-PCR) (OIE, 2019).
The selection of the laboratory test to be used each time depends on the epidemiological situation
(e.g. presence of clinical signs, vaccination, endemic areas), the purpose of the sampling, the sample
matrices, the results of the previous tests and the capacity of the laboratories (Table 3).
Figure 3: Minimum sample size, to detect animals with clinical signs with confidence level of 95%,
assuming design prevalence of 2%, using different sensitivity levels for the clinical
examination (Se.: 30%, 50%, 70%, 90%)
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Given that for clinically affected animals the sensitivity of the PCR assays in epithelium is higher
than 95% and the sensitivity of the Ag-ELISA is 83%, the suggested strategy in the event of suspicion
of FMD in an establishment is to take samples from the animals with clinical signs selected as
described above.
Samples for the laboratory analysis must be collected first from animals exhibiting prominent FMD
lesions, and then from animals showing less specific clinical signs, samples must be sent to the
laboratory without delay.
In animals where lesions are detected, and assuming that the specificity of the clinical examination
is 100% (no false positive results), and with a sensitivity of the PCR in epithelium from lesions higher
than 95%, sampling one animal would be enough to detect FMD with 95% confidence.
However, the specificity of the clinical examination is assumed less than 100% (see Assessment),
implying that the confidence would drop, because an FMD false positive animal (animal considered
clinically positive for FMD but not infected by FMDV) could be submitted for testing. This is particularly
relevant at a low design prevalence (2%).
Assuming i) a specificity of the clinical inspection of 99% (see above) (indicating that 1 in every
100 non-infected animals is considered clinically positive), ii) a design prevalence of 2% and iii) a
sensitivity of clinical examination of 90% in naive cattle and pig populations, then the positive
predictive value (the probability that a selected animal clinically classified as positive is truly FMD
infected) would be 65% (see equation 1 in Section 3.1.1).
The overall probability to detect FMD by PCR with a single sample of epithelium from lesions would
be 63% for 3D rRT-PCR and 64% for the combined 3D rRT-PCR and 50UTR rRT-PCR in parallel (Table 2
and equation 2 in Section 3.1.1). If Ag-ELISA is used instead of PCR, this probability would be 54%.
In order to detect an outbreak with at least 95% confidence, samples from at least four animals
need to be sent to the lab for Ag-ELISA, whereas at least three samples would suffice for the single
PCR and combined PCR (3D rRT-PCR and 50UTR rRT-PCR performed in parallel) (Table 4 and
equation 4 in Section 3.1.1). For 99% confidence, sample sizes need to be increased at least to 5 for
PCR and to 6 for Ag-ELISA (Table 4 and equation 4 in Section 3.1.1).
The sensitivity of the clinical diagnosis is assumed 30% in sheep and goat establishments, animals
in endemic areas and vaccinated animals (see Assessment). The overall probability to detect FMD by
Table 3: The preferable sample matrices and the preferable tests for each animal species when
clinical signs are present (suspicion) and when clinical signs are not present (preventing
killing; testing clinically healthy animals before movement)
Cattle/Pigs/Sheep and Goats
Sample matrices Laboratory tests
Clinical signs Epithelium, Skin lesions,
EDTA-blood,
Serum, Saliva swabs, Milk
1st step: 3D rRT-PCR + 50UTR rRT-PCR;
Ag-ELISA against all FMDV serotypes;
VI
2nd step: In case one of the tests above is positive:
FMDV-VP1 sequencing;
FMDV serotype specific RT-PCRs
3rd step: For more detailed molecular epidemiology:
Complete Coding Sequencing or WGS
No clinical
signs
Serum; EDTA-blood; Milk 1st step: Serum: SP or NSP-Ab-ELISA for non-vaccinated animals;
Serum: NSP-Ab-ELISA for vaccinated animals;
Milk: 3D rRT-PCR + 50UTR rRT-PCR
2nd step: In case Ab-ELISA is positive:
3D rRT-PCR + 50UTR rRT-PCR;
VI
3rd step: In case rRT-PCR or VI is positive:
FMDV-VP1 sequencing;
FMDV serotype specific RT-PCRs
4th step: For more detailed molecular epidemiology:
Complete Coding Sequencing or WGS
VI: virus isolation; Ag: antigen; Ab: antibody; SP: structural proteins; NSP: non-structural proteins; WGS: whole genome
sequencing; rRT-PCR: real-time Reverse Transcription Polymerase Chain Reaction; VP1: Viral Protein 1.
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PCR with a single sample of epithelium from lesions would be 37% for 3D rRT-PCR and the combined
3D rRT-PCR and 50UTR rRT-PCR in parallel (Table 1 and equation 2 in Section 3.1.1). If an Ag-ELISA is
used instead of PCR, this probability is 32%.
In order to detect an outbreak with at least 95% confidence, samples from at least 7 animals need
to be sent to the laboratory if a PCR is used and at least 8 in case Ag-ELISA is used (Table 4 and
equation 4 in Section 3.1.1). For 99% confidence, sample sizes need to be increased to 10 for single
and combined 3D rRT-PCR and 50UTR rRT-PCR in parallel and to 13 for Ag-ELISA (Table 4 and
equation 4 in Section 3.1.1).
According to Table 1, the test sensitivity of the PCR in serum is not significantly different from that
in epithelium and, consequently, the same number of samples can be taken for blood as for epithelium
(Table 4).
In summary, to ensure an overall 95% confidence of FMD detection, samples from epithelium from
lesions from at least four clinically positive animals are required in previously naive cattle and pig
populations. For sheep and goats, this number should increase to 7–8 animals.
Table 4: Examples of the minimum number of samples needed to be collected from animals with
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In case no clinical signs are seen, sampling for laboratory examination will follow the procedures
described in Section 4.1.1.2 for animals without clinical signs.
Taking different types of samples from each animal (epithelium from different lesions, oral swabs,
blood) will increase the confidence to detect or rule out the disease and can prevent technical
problems with sampling in the field (e.g. low quality of samples and difficulties to collect samples
especially for the epithelium).
In addition, increasing the sensitivity of the clinical examination through well-trained veterinarians
performing a thorough individual clinical examination will also increase the level of confidence and
decrease the number of samples needed for laboratory examination (Figure 4).
4.1.1.2. For the purposes of the epidemiological enquiry as referred to Article 57 of
Regulation (EU)2016/429 in an establishment affected and officially confirmed
with FMD
The purpose of this section is to assess the effectiveness of disease-specific sampling procedures,
based on laboratory examination (ToR 1.2), in their ability to detect the disease in the event of
preventive killing and in their ability to support with the epidemiological investigation (disease
detection, prevalence estimation, virus identification, etc.) in kept animals of listed species in an
affected establishment, before or when they are killed or found dead. The purposes of the
epidemiological enquiry are described in Article 57 of Regulation (EU)2016/429. For further details, see
Annexes B and C.
Figure 4: Minimum sample size needed to achieve 95% confidence in detecting one infected animal,
based to the sensitivity of the clinical examination and the sensitivity of 3 different
laboratory tests (Ab Ag ELISA, Se: 83.3%; 3D rRT-PCR, Se: 97.7%; 3D rRT-PCR and 50UTR
rRT-PCR in parallel Se: 99.5%), using different values for Design Prevalence (1%, 2%, 3%,
4%, 5%)
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Summary of sampling procedures
Council Directive 2003/85/EC: ‘2.1.2. To carry out an epidemiological investigation and where
sampling is carried out in the framework of disease surveillance after an outbreak, actions shall not
commence before at least 21 days have elapsed since the elimination of susceptible animals on the
infected holding(s) and the carrying out of preliminary cleansing and disinfection, unless otherwise
provided for in this Annex.’
Assessment
To support the epidemiological investigation when an affected establishment is officially confirmed,
disease-specific sampling procedures based on laboratory examination should be performed.
When FMD has been officially confirmed in an establishment, further sampling procedures will
support the needs of the epidemiological enquiry to obtain information on the origin of the disease,
the length of time that the disease is present. In addition, in case preventive killing is decided,
sampling procedures will confirm or rule out the disease.
Development of new procedures
Estimate the prevalence of animals with clinical signs within the affected establishment
The prevalence of animals with clinical signs in an affected establishment may help to understand
how widespread the infection is within the establishment and for how long it has been present.
For this purpose, when feasible, animals that are still alive or those that are found dead or were
culled should be examined to identify clinical signs and lesions compatible with FMD. A brief visual
inspection of the mouth and feet of the animals is sufficient for this purpose and in case that is not
feasible due to a large population, it is recommended to examine at least 100 animals (allows
estimation of 50% prevalence with an accepted error of 10% with 95% confidence). The prevalence
of animals with clinical signs and lesions within the establishment can be estimated based on these
examinations.
Estimate the length of time that the disease is present in the establishment
The estimation of the age of the lesions could contribute to the epidemiological investigation by
providing information on the most likely time and pathway of introduction of FMD into the
establishment and consequently support the quick tracing of the contacts.
The estimation of the age of the lesions in cattle in the field is generally more accurate when
performed up to 5 days after infection by an experienced veterinarian; thereafter the accuracy
decreases probably due to secondary bacterial infections of the lesions that may change their
• 2nd scenario of sampling procedures
• ToR 1.2 in accordance with Article 12(3) and the Art. 7 (4) (Preventive killing) of the Delegated
Regulation (EU) 2020/687
• Article 57 of the Regulation (EU) 2016/429
The following elements of the scenario should be taken into consideration for the assessment:
1) It concerns an affected establishment officially confirmed
2) Kept animals of listed species found dead or before/when they are killed are sampled
3) The competent authority shall collect samples for laboratory examination
4) The purposes of the sampling are:
a) to support the epidemiological enquiry:
i) to identify the likely origin of the disease;
ii) to calculate the likely length of time that the disease has been present;
iii) to identify establishments where the animals could have contracted the disease and
movements from the affected establishment that could have led to the spread of the disease;
and
iv) to obtain information on the likely spread of the listed disease in the surrounding
environment, including the presence and distribution of disease vectors
b) to confirm/rule out disease in the event of preventive killing
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appearance (Alexandersen et al., 2003a; DEFRA, 2005; Ryan et al., 2008; EuFMD, 2020a). There is
training material available by EuFMD-FAO4 that can support veterinarians in the field with this process.
The clinical examination should be thorough as the lesion age may vary even in the same animal, with
the oldest ones being more important for the epidemiological investigation.
Supplementary information to support the estimation of the time of infection can be provided by
the presence or lack of antibodies in animals with clinical signs in an affected establishment.
Circulating antibodies against FMDV can be detected by SP-ELISA (e.g. Solid phase competition ELISA)
as early as 3–5 days after the first appearance of clinical signs, reaching a high level 2–4 days later
(5–9 days after the appearance of clinical signs). The earliest detection of antibodies by virus
neutralisation test (VNT) is usually 1–2 days later (Alexandersen et al., 2003b). Following experimental
infection, NSP seroconversion takes sometimes 7 days but more often 9–14 days (Paton et al., 2014).
Collect samples for virus isolation and to identify the likely origin of the disease.
Since the disease has been confirmed in the establishment and assuming this has not been already
done during the investigation of the suspicion, some additional samples may be taken for virus
isolation according to the instructions provided by the laboratory. It is particularly important to collect
samples, in case clinical signs are present, for those groups of animals in the establishment not
sampled previously. The reason is that this may help to identify the origin of the infection or possible
onward spread. Material for virus isolation should be collected preferably within the first week of the
occurrence of clinical signs, before the development of neutralising antibodies. A range of sample
types, including epithelium, OP samples, milk and serum, may be examined by virus isolation.
Sequencing a part of the FMDV genome like VP1 can be enough to determine the origin of the
virus (Ularamu et al., 2020). VP1 sequencing also allows the reconstruction of phylogeographic
transitions of FMDV strains across and within countries (Bachanek-Bankowska et al., 2018). Using
whole genome sequencing (WGS) a higher resolution is obtained and so it is possible to compare FMD
viruses from different establishments and to define the virus pathway between establishments during
the epidemic (Cottam et al., 2008).
Confirm the disease in case a preventive killing is decided
In the Delegated Regulation, preventive killing may be implemented for the animals of listed
species for FMD (i.e. members of the orders Artiodactyla, Proboscidea) in three cases: i) in an
establishment suspected of FMD, ii) in the establishments in temporary restricted zones and iii) in the
establishments of the restricted zone (that is the protection and surveillance zones and further
restricted zones).
In case preventive killing is applied, all the animals in the establishment should be subjected to
individual clinical examination to identify animals with clinical signs and the whole procedure as
described in the first scenario in the event of the suspicion of the disease, should be implemented.
In the absence of clinical signs, the confirmation of FMD will be based on the results of laboratory
examinations (Ab-ELISA, RT-PCR) on a sample of animals of the establishment. The samples to be
collected are serum, EDTA-blood or milk from a sample of animals. The sample size in the examples is
stratified according to the various groups of animals present in the establishment.
Examples for different herd sizes and different sample matrices (EDTA-blood and serum) are
presented in Table 5, assuming a design prevalence of FMD (5%). The design prevalence had to be
adjusted for herd sizes where n ≤ 10 to reflect the assumption of at least one animal being infected.
The values for the sensitivity of the laboratory tests used for each type of sampled matrix, are
those presented in Table 5.
4 An online tool with images of FMD lesions in cattle, sheep, goats and pigs in the field is available in EuFMD Lesion Library.
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FMDV can be detected in milk up to 4 days before the appearance of clinical signs (OIE, 2013).
Therefore, milk samples can be collected from individual animals and tested by PCR methods to detect
the presence of FMDV at early stage. A study by Armson et al. (2018) shows that collecting milk from
bulk storage tanks would allow to detect the presence of FMDV in a dairy cattle herd in an easy and
non-invasive way. The findings of this study indicate that it could be possible to identify one acutely-
infected milking cow in a typical sized dairy herd (100–1,000 individual) using bulk milk sampling
(Armson et al., 2018).
4.1.1.3. For granting a specific derogation from killing animals of the categories of article
13.2 of the Delegated Regulation in an FMD affected establishment
The purpose of this section is to assess the effectiveness of disease-specific sampling procedures
based on clinical (ToR 1.1) and laboratory (ToR 1.2) examinations of the animals of listed species
belonging to the categories described in article 13(2) of an affected establishment, in order to grant a
specific derogation from killing these animals, while ensuring that they do not pose a risk for the
transmission of the disease. For further details, see Annexes B and C.
Table 5: Sample size to achieve a confidence level of 95% (probability of detecting or ruling out
the presence of FMD) in an establishment assuming a design prevalence of 5%, by using
PCR on EDTA-blood and NSP-ELISA or SPC-ELISA on serum. The values of the sensitivity
of the laboratory tests are those presented in Table 1
RT-PCR on EDTA-blood
(Se = 98.8%)
















































































10 10%* 10 98% 10%* 10 100% 10%* 10 67%
20 5% 20 95% 5% 19 95% 5% 20 67%
50 5% 39 95% 5% 39 95% 5% 50 90%
100 5% 45 95% 5% 45 95% 5% 66 95%
200 5% 52 95% 5% 51 95% 5% 75 95%
250 5% 55 95% 5% 55 95% 5% 80 95%
300 5% 54 95% 5% 54 95% 5% 80 95%
500 5% 56 95% 5% 56 95% 5% 82 95%
750 5% 57 95% 5% 56 95% 5% 83 95%
1,000 5% 58 95% 5% 57 95% 5% 84 95%
*: The minimum number of animals being infected in a herd is one. Therefore, the values for the design prevalence provided
here is the result of the ratio between 1 and the herd size.
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Summary of sampling procedures
No specific guidelines on sampling procedures for clinical or laboratory examination were found for
the third scenario.
Assessment
In an FMD-affected establishment, there might be animals, incubating FMD which have not been
detected by laboratory tests carried out. Furthermore, among ruminants, some animals may become
‘carriers’ following their exposure, and this needs to be taken into consideration when interpreting diagnostic
test results. The duration of the carrier state varies with the host species as explained in Section 2.1.
The percentage of animals that become carriers under experimental conditions is variable but is on
average around 50% (Alexandersen et al., 2003b); A study by Arnold et al. (2008) showed that the
expected prevalence of herds containing carrier-animals after reactive vaccination is likely to be very
low, approximately 0.2%; and there will only be a small number of carriers, most likely one, in the
infected herds. The virus can be recovered intermittently from such carrier animals from OP samples
(Geering and Lubroth, 2002).
Development of new procedures
Regular clinical examination should be carried out, preferably every day, to detect early the onset of
clinical signs, for a period of at least the existing monitoring period of 21 days calculated forwards
from the day of confirmation of the latest case in the establishment.
All the animals intended for derogation from killing should be subjected to thorough individual clinical
examination and samples for laboratory examination should be collected from all the animals irrespectively
of the presence of clinical signs. This will enable identification of infected animals which have no clinical
signs, to estimate the prevalence of FMD in the establishment and to evaluate the risk. Sampling for
laboratory examination can be repeated at any time, but the last sampling should be carried out not earlier
than 21 days calculated forwards from the day of confirmation of the latest case within the establishment.
Sampling procedures for laboratory examinations in order to detect or rule out the presence of FMD
virus should follow the procedures described in Section 4.1.1.2.
4.1.1.4. For the animals of non-listed species kept in an FMD affected establishment
The purpose of this section is to assess the effectiveness of disease-specific sampling procedures,
based on clinical (ToR 1.1) and laboratory (ToR 1.2) examinations of the animals of non-listed species
kept in an affected establishment, in their ability to ensure the detection of the virus if the virus is
present in these species. For further details, see Annexes B and C.
• 3rd scenario of sampling procedures
• ToR 1.1 and ToR 1.2 in accordance with Article 13(3)c of the Delegated Regulation (EU) 2020/687
The following elements of the scenario should be taken into consideration for the assessment:
1) It concerns an affected establishment where infection is officially confirmed
2) In the establishment there are kept animals of listed species of the following specific categories
animal categories based on article 13(2):
a) animals kept in a confined establishment
b) animals kept for scientific purposes or purposes related to conservation of protected or
endangered species
c) animals officially registered in advance as rare breeds
d) animals with a duly justified high genetic, cultural or educational value
3) The competent authority may grant specific derogation from killing all the animals of listed species
belonging to any of the above categories in an affected establishment, provided that specific
conditions are fulfilled
4) The animals should be subjected to clinical surveillance, including laboratory examinations
5) Sampling procedures should ensure that the animals do not pose a risk of transmission of the
category A disease if left alive
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Summary of sampling procedures
No specific guidelines on sampling procedures for clinical or laboratory examination were found for
the fourth scenario.
Council Directive 2003/85/EC: In the Article 2 (a): ‘animal of a susceptible species’ means any
domestic or wild animal of the suborders Ruminantia, Suina, and Tylopoda of the order Artiodactyla.
For specific measures, notably in application of Article 1(2), Article 15 and Article 85(2), other animals,
such as for example of the order Rodentia or Proboscidae, may be considered susceptible to foot-and-
mouth disease in accordance with scientific evidence.’
Assessment
In scientific literature, FMDV natural or experimental infection has been reported in several species
other than the Artiodactyla and Proboscidea, although not confirmed by virus isolation or virus
detection in all of the cases, and without evidence on their role on the epidemiology (transmission,
persistence) of the disease (Thomson et al., 2003; Weaver et al., 2013). The list of orders and species
includes Carnivora (bears, minks), Chiroptera (vampire bat), Cingulata (armadilos), Didelphimorphia
(possum), Diprotodontia (kangaroos, potoroos, wombats), Eulipotyphla (hedgehogs, moles),
Hyracoidea (hyrax), Peramelemorphia (bandicoot), Lagomorpha (rabbits), Rodentia (agoutis, capybara,
chinchilla, coypu, gerbils, guinea pigs, mole-rats, porcupine, rats, squirrels, vole) (Weaver et al., 2013).
Some older publications reported suspicion that the European (Erinaceus europaeus) and East
African (Atelerix prurei hindu) hedgehogs were involved in FMD outbreaks in livestock; however, there
is no further evidence of their role in FMD spread in recent epidemics in Europe, and there is no report
over the last 50 years (Weaver et al., 2013).
Armadillo (Chaetophractus villosus) and capybaras (Hydrochaeris hydrochaeris) can transmit the
FMDV to cattle and pigs under experimental conditions, but there was no evidence of transmission to
livestock in the field in Central and South America (Weaver et al., 2013).
FMDV can be experimentally transmitted (usually through intradermal or intradermolingual
inoculation) in several species of the orders Rodentia and Lagomorpha that are commonly used as
laboratory animals but also in cats, puppies, goldfish and jackdaws (Weaver et al., 2013). Following
inoculation of FMDV, the animals developed clinical signs and some of them died (Thomson et al.,
2003; EFSA AHAW Panel, 2006; Weaver et al., 2013). Nevertheless, this does not imply that these
species can be infected under natural conditions and there is no evidence of their role in the
epidemiology of FMD in the field (EFSA AHAW Panel, 2006; Weaver et al., 2013).
Development of new procedures
Several of the species mentioned above are not natural inhabitants of the European continent, and
the role of those that are natural inhabitants of the European continent on FMD transmission is
debated. Nevertheless, if they are kept in an establishment affected by FMD, they should be monitored
for clinical signs. On the occurrence of clinical signs, samples should be collected for laboratory
analysis.
• 4th scenario of sampling procedures
• ToR 1.1 and ToR 1.2 in accordance with Article 14(1) of the Delegated Regulation (EU) 2020/687
• Article 57 of the Regulation (EU) 2016/429
• Commission Implemented Regulation 2018/1882 on listed species
The following elements of the scenario should be taken into consideration for the assessment:
1) It concerns an affected establishment officially confirmed
2) In the affected establishment there are kept animals of non-listed species of epidemiological
relevance for the control of the disease
3) Animals of non-listed species are those animals that are not listed in Commission Implementing
Regulation (EU) 2018/1882 for each of the category A diseases
4) The animal species acting purely as mechanical carriers of the virus will not be covered
5) The competent authority is not obliged to carry out the sampling of non-listed species, but they may
establish it in addition to other measures
6) The purpose of the sampling procedures is to ensure detection of the virus in these species
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The clinical examination and the sampling for laboratory analysis should be carried out as described
in Sections 4.1.1.1 and 4.1.1.2. Nonetheless, the lack of information on the performance of laboratory
tests (sensitivity, specificity) in these animal species along with the lack of validation of the diagnostic
methods in them will increase the uncertainty on the reliability of the sampling strategy.
4.1.1.5. For wild animals of the listed species within the FMD affected establishment and
its surroundings
The purpose of this section is to assess the effectiveness of disease-specific sampling procedures,
based on clinical (ToR 1.1) and laboratory (ToR 1.2) examinations of the wild animals of listed species
within the affected establishment and in its surroundings. The purpose of the sampling procedures is
to ensure the detection of the virus, if the virus is present in these wild species. For further details, see
Annexes B and C.
Summary of sampling procedures
No specific guidelines on sampling procedures for clinical or laboratory examination were found for
the fifth scenario.
Assessment
Based on the review of Weaver et al. (2013), several wild animals of listed species for FMD have
been reported to be infected and all seven serotypes of FMDV have been detected.
In most of the cases, infection of wild animals of listed species seems to be secondary, in proximity
to outbreaks in domestic livestock and have been reported in endemic areas during/after epidemics in
domestic animals. Surveys in wildlife (cervids, wild boar,) conducted in Europe suggested that FMD did
not become established in the wildlife and it could not be maintained in the absence of FMD in
domestic animals (EFSA AHAW Panel, 2012; Alexandrov et al., 2013; Weaver et al., 2013) (EFSA
AHAW Panel, 2012; Weaver et al., 2013). An exception could be for African buffaloes (Syncerus caffer)
and some species of antelope that are not natural inhabitants of the European Continent.
Genetic and epidemiological data indicated the involvement of African buffaloes in FMDV
transmission to cattle populations and their role as reservoir of the three African serotypes (SAT 1,2,3)
(Thomson et al., 2003; Weaver et al., 2013).
Occasionally, FMD can cause die-offs of wildlife, as apparently occurred in South Africa in the late
19th century where large numbers of impalas (Aepyceros melampus) died, and in Israel where high
mortality occurred in mountain gazelles (Gazella gazella) (Thomson et al., 2003; Weaver et al., 2013).
There is no evidence to demonstrate the epidemiological involvement of wild animals of listed for
FMD species in the spread or maintenance of FMDV. Nonetheless, it is feasible that they could act as
spill over hosts and so potentially could be a source of infection for livestock.
Development of new procedures
The detection of FMD in wildlife is more complicated than in kept animals not only because of the
variation in hosts and virus serotypes but also of the practical difficulties and limitations of surveillance
and monitoring activities of wildlife in the natural environment.
• 5th scenario of sampling procedures
• ToR 1.1 and ToR 1.2 in accordance with Article 14(1) of the Delegated Regulation (EU) 2020/687
• Article 57 of the Regulation (EU) 2016/429
• Commission Implemented Regulation 2018/1882 on listed species
The following elements of the scenario should be taken into consideration for the assessment:
1) It concerns an affected establishment officially confirmed
2) They may exist wild animals of listed species within the establishment and in the surroundings of the
establishment
3) As listed in Commission Implementing Regulation (EU) 2018/1882 for FMD; the wild animals of listed
species animals are those of Artiodactyla and Proboscidea
4) The competent authority may establish these sampling procedures in addition to other measures
5) The purpose of the sampling procedures in wild animals of listed species is to ensure the detection of
the virus, if the virus is present in these wild species
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The surveillance of wildlife around the affected establishment may include the visual inspection of
these animals from a distance and the inspections of any dead animals found, and hunted, trapped
animals to identify clinical signs and lesions compatible with FMD.
Samples from dead, hunted or trapped animals should be collected for laboratory analysis,
following the procedures of Section 4.1.1.2. Wildlife population health experts would be able to
provide additional advice in these circumstances. In addition, it may be possible to collect samples
from some wild animal species using non-invasive methods such as salt licks and chewing ropes or
baits (Vosloo et al., 2013; Mouchantat et al., 2014).
Nonetheless, the lack of information on the performance of laboratory tests (sensitivity, specificity)
in these animal species along with the lack of validation of the diagnostic methods in them will
increase the uncertainty of the reliability of the sampling strategy.
4.1.1.6. For non-affected establishments located in a protection zone
The purpose of this section is to assess the effectiveness of disease-specific sampling procedures
based on clinical (ToR 1.1) and laboratory (ToR 1.2) examinations of the animals of listed species in
establishments located in the protection zone. The purpose of the sampling procedures is to ensure
the detection of the virus if the virus is present in these animals. For further details, see Annexes B
and C.
Summary of sampling procedures
No specific guidelines on sampling procedures for a clinical or laboratory examination were found
for the sixth scenario.
Assessment
For FMD, the minimum radius for the protection zone is 3 km and 10 km for the surveillance zone
(Annex V of the Delegated Regulation). An assessment of the effectiveness of the length of the radius
of the protection and surveillance zone is presented in Section 4.3.1 and is based on kernels
estimations.
According to the assessment for the length of the radius of the protection zone, the median
probability of one affected establishment to transmit FMD to another establishment located up to 3 km
(within the current protection zone) is 95.2%.
Development of new procedures
All establishments located in the protection zone should be visited and all the animals should be
clinically examined. Visual inspection of the herd at first place would be very helpful to identify animals
with lameness, excessive salvation, reluctance to move and those that are remaining isolated and
separated from the herd.
In an establishment where the number of animals is large, the individual clinical examination of all
the animals may not be feasible. In this case a minimum sample of animals should be clinically
examined, to detect or rule out, at a 95% confidence level or higher, the presence of animals with
clinical signs, as described in Section 4.1.1.1.
Since some animals may not show pathognomonic signs in early stages (or in the event of mild
cases, as it can occur in sheep and goat herds), the clinical investigation should also focus on some
early or more generic signs of the disease such as fever, lethargy, lost appetite, lameness, salivation,
nasal discharge, reluctance to move or found separated and isolated from the herd. In addition, it is
• 6th scenario of sampling procedures
• ToR 1.1 and ToR 1.2 in accordance with Article 26(2) of the Delegated Regulation (EU) 2020/687
The following elements of the scenario should be taken into consideration during for the assessment:
1) It concerns the protection zone with radius up to 3 km
2) Official veterinarians must visit at least once all the non-affected establishments with kept animals of
listed species located in the protection zone
3) Among others, they must perform a clinical examination of kept animals of listed species and if
necessary, collection of samples for laboratory examination
4) The purpose of sampling procedures is to confirm or rule out the presence of a category A disease
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necessary to collect further information on the health history of the establishment and the records and
documents to be reviewed in order to identify evidence of the presence of the disease such as:
morbidity, mortality, clinical observations, changes in productivity and feed intake, purchase or sale of
animals, visits of persons likely to be contaminated, transport of animals from holding or areas at risk.
For cattle and pigs, clinical examination would be enough as a typical clinical manifestation of FMD
is expected in these species. There is no need for laboratory examination if there are no other reasons
based on the national risk assessment to recommend so (e.g. epidemiological link with affected
establishment or with affected or high-risk area).
Sheep, goats and animals that have been vaccinated or located in endemic areas (if such scenario
ever arises in the European Union) have a less prominent clinical manifestation when infected and
therefore laboratory examinations should be considered.
The sampling should be able to detect or rule out the presence of FMD, with a confidence level at
least of 95% as described in sampling procedures in Section 4.1.1.2 and in Table 5.
Collecting the number of samples according to Table 5 for detecting antibodies against non-
structural proteins (NSP) (indicative for multiplication of the FMDV and therefore the NSP-ELISA can be
used as a DIVA test in case of vaccinated animals), depending on the sensitivity of the test allows
detection of at least one seropositive animal with 95% confidence if 5% or more are seropositive.
4.1.1.7. For non-affected establishment located in a surveillance zone
The purpose of this section is to assess the effectiveness of disease-specific sampling procedures,
based on clinical (ToR 1.1) and laboratory (ToR 1.2) examinations of the animals of listed species, for
the sampling of the establishments located within the surveillance zone. The purpose of the sampling
procedure is to ensure disease detection if the virus is present in establishments within the surveillance
zone. For further details, see Annexes B and C.
Summary of sampling procedures
No specific guidelines on sampling procedures for a clinical or laboratory examination were found
for the eighth scenario.
Assessment
For FMD, the minimum radius for the protection zone is 3 km and 10 km for the surveillance zone
(Annex V of the Delegated Regulation). An assessment of the effectiveness of the length of the radius
of the protection and surveillance zone is presented in Section 4.3.1 and is based on kernels
estimations.
According to the assessment for the length of the radius of the protection and the surveillance
zone, the median probability of one affected establishment to transmit FMD to another establishment
located beyond 3 km (outside the current protection zone) if transmission occurred, is 4.8%.
In case the surveillance activities do not identify any other affected establishments in the protection
zone, the likelihood of FMD having escaped beyond the limits of the protection zone into the
surveillance zone is very low.
Development of new procedures
For the surveillance zone, it is recommended that the efforts will be allocated to enhance passive
surveillance by increasing awareness in all establishments, industry and public. In addition, the
• 8th scenario of sampling procedures
• ToR 1.3 in accordance with Article 41 of the Delegated Regulation (EU) 2020/687
The following elements of the scenario should be taken into consideration during for the assessment:
1) Ιt concerns the surveillance zone
2) Sample of the establishments of kept animals of listed species in the surveillance zone
3) Official veterinarians carry out visits to a sample of the establishments among others perform clinical
examination of kept animals of listed species and if necessary, collection of samples for laboratory
examination
4) The purpose of sampling procedure is to ensure the detection of the disease if the disease is present in
any of the establishments
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awareness of the veterinarians at the slaughterhouses should be high during the ante-mortem animal
inspection and post-mortem inspection of the mouth and the feet in particular for sheep and goats.
Any establishment where more generic signs of the disease such as fever, lethargy, lost appetite,
nasal/oral discharge, lameness and even changes in the individual animal behaviour, in the feed intake
and productivity are reported should be visited, the animals should be clinically examined and samples
should be collected following the procedures described in Sections 4.1.1.1 and 4.1.1.2.
Establishments in the surveillance zone epidemiologically linked to an affected establishment or to
any other establishment in the protection zone should be also visited; the animals should be clinically
examined, and samples should be collected in case a suspicion is raised following the procedures
described in Sections 4.1.1.1 and 4.1.1.2.
4.1.2. Assessment of sampling procedures to grant derogations for animal
movements
4.1.2.1. From non-affected establishments located in the protection zone to
slaughterhouses located within the protection zone or in the surveillance zone or
outside the restricted zone
The purpose of this section is to assess the effectiveness of disease-specific sampling procedures
based on clinical and/or laboratory examinations of the animals of an establishment in a protection
zone, in order to grant a derogation from prohibitions in the movement of animals, and allow for the
animals to be moved to a slaughterhouse located within the protection zone or in the surveillance zone
or outside the restricted zone (Art29). For further details, see Annexes B and C.
Summary of sampling procedures
No specific guidelines on sampling procedures for clinical or laboratory examination were found for
the ninth scenario in EU legislation.
Assessment
This scenario includes three different subscenarios: a) the need to transfer animals of listed species
for FMD kept in establishments located in the protection zone to a slaughterhouse located within the
protection zone; b) the need to transfer animals of listed species for FMD located in the protection
zone to a slaughterhouse located within the surveillance zone; and c) the need to transfer animals of
listed species for FMD located within the protection zone to slaughterhouse located outside the
restricted zone.
During FMD outbreaks, there is risk of undiagnosed infected animals being moved and spreading
the disease, and this should be considered when designing animal movement derogations. The highest
risk of spread due to movement of undiagnosed animals is associated with subscenario c, then b and
finally a. Nevertheless, the fact that the destination of these animals is the slaughterhouse, all
biosecurity measures are implemented and given that the animals should be slaughtered within 24 h
reduces the risk. In addition, animal slaughtering from the establishments in the protection zone could
have beneficial effect encompassing the reduction of the number of potential hosts for the further
spread of FMDV.
• 9th scenario of sampling procedures
• ToR 1.4 in accordance with Article 28(5) of the Delegated Regulation (EU) 2020/687
• Article 29 of the Delegated Regulation
The following elements of the scenario should be taken into consideration during for the assessment:
1) It concerns the protection zone
2) Grant derogation for movement of kept animals of listed species from a non-affected establishment in
the protection zone
3) Animals to be moved to a slaughterhouse located within the protection zone or in the surveillance zone
or outside the restricted zone
4) Clinical examinations and laboratory examination of animals kept in the establishment, including those
animals to be moved
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Development of new procedures
All the animals in the establishment of origin should be clinically examined before their movement,
following the procedures described in Section 4.1.1.1. Visual inspection of the herd would be very
helpful to identify animals with lameness, excessive salvation, reluctance to move and those that are
remaining isolated and separated from the herd.
In an establishment where the number of animals is large, the individual clinical examination of all
the animals may not be feasible; in this case a minimum sample of animals (including all animals to be
moved) should be clinically examined to detect or rule out the presence of animals with clinical signs
with at least 95% confidence, as described in Section 4.1.1.1.
In case clinical signs compatible with FMD are identified, the establishment is considered suspected
and the procedures for the laboratory confirmation that are described in Section 4.1.1.1 should be
followed and any movements should be prohibited.
If animals of listed species for FMD of an establishment located in the protection zone are to be
dispatched to slaughterhouses located outside the restricted zone (subscenario c), then in addition to
the clinical examination, sampling for laboratory examination should be performed following the
procedures described in Section 4.1.1.2, in order to exclude infected but subclinical animals.
4.1.2.2. From non-affected establishments located in the protection zone to a plant
approved for processing or disposal of animal by-products in which the animals
are immediately killed
The purpose of this section is to assess the effectiveness of disease-specific sampling procedures
based on clinical and/or laboratory examinations of the animals of an establishment in a protection
zone, in order to grant derogation from prohibitions in the movement of these animals to a plant
approved for processing or disposal of animal by-products in which the kept animals are immediately
killed (Art. 37). For further details, see Annexes B and C.
Summary of sampling procedures
No specific guidelines on sampling procedures for clinical or laboratory examination were found for
the 12th scenario in EU legislation.
Assessment
This scenario is very similar to the ninth scenario of Section 4.1.3.1, and therefore, the assessment
is the same.
Development of new procedures
This scenario is very similar to the ninth scenario of Section 4.1.3.1; therefore, the same
procedures are suggested.
4.1.2.3. From an establishment in a surveillance zone to a slaughterhouse located within
or outside the restricted zone and from an establishment outside the surveillance
zone to a slaughterhouse situated in the surveillance zone
The purpose of this section is to assess the effectiveness of disease-specific sampling procedures
based on clinical and/or laboratory examinations of the animals of listed species in order to grant
• 12th scenario of sampling procedures
• ToR 1.4 in accordance with article 28(5) and article 37 of the Delegated Regulation (EU) 2020/687
The following elements of the scenario should be taken into consideration during for the assessment:
1) It concerns the protection zone
2) To grant derogation for movement of kept animals of listed species from a non-affected establishment
in the protection zone
3) The animals to be moved to a plant approved for processing or disposal of animal by-products in which
the kept animals are immediately killed
4) Clinical examinations and laboratory examinations of animals kept in the establishment, including those
animals to be moved
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derogation from prohibitions and allow for these animals to be moved: a) from an establishment in a
surveillance zone to a slaughterhouse located within or outside the restricted zone, b) from an
establishment outside the surveillance zone to a slaughterhouse situated in the surveillance zone. For
further details, see Annexes B and C.
Summary of sampling procedures
No specific guidelines on sampling procedures for clinical or laboratory examination were found for
the 13th scenario in EU legislation.
Assessment
This scenario includes three different subscenarios: a) the need to transfer animals of listed species
for FMD kept in establishments located in the surveillance zone to a slaughterhouse located within the
surveillance zone; b) the need to transfer animals of listed species for FMD located in the surveillance
zone to slaughterhouse located outside the surveillance zone; and c) the need to transfer animals of
listed species for FMD located outside the surveillance zone to slaughterhouse located within the
surveillance zone. The highest risk of spread is associated with the subscenario b) where animals move
from a higher risk zone to a lower risk zone.
Development of new procedures
All the animals in the establishment of origin should be clinically examined before their movement
following the procedures described in Section 4.1.1.1. Visual inspection of the herd would be very
helpful to identify animals with lameness, excessive salvation, reluctance to move and those that are
remaining isolated and separated from the herd.
In an establishment where the number of animals is large, the individual clinical examination of all
the animals may not be feasible; in this case a minimum sample of animals (including all animals to be
moved) should be clinically examined to detect or rule out the presence of animals with clinical signs
with at least 95% confidence, as described in Section 4.1.1.1.
In case clinical signs compatible with FMD are identified, the establishment is considered suspected
and the procedures for the laboratory confirmation that are described in Section 4.1.1.1 should be
followed and any movements should be prohibited.
If the dispatch of animals of listed species for FMD located in the surveillance zone is to
slaughterhouses located outside the surveillance zone (subscenario b), then in addition to clinical
examination, sampling for laboratory examination should be performed following the procedures
described in Section 4.1.1.2, in order to exclude infected but subclinical animals.
4.1.2.4. From an establishment in a surveillance zone to pastures situated within the
surveillance zone
The purpose of this section is to assess the effectiveness of disease-specific sampling procedures
based on clinical and/or laboratory examinations of kept ungulates of listed species in order to grant a
derogation and allow the animals to be moved from an establishment in the surveillance zone to
pastures situated within the surveillance zone. For further details, see Annexes B and C.
• 13th scenario of sampling procedures
• ToR 1.4 in accordance with article 43(5) and article 44 of the Delegated Regulation (EU) 2020/687
The following elements of the scenario should be taken into consideration during for the assessment:
1) It concerns kept animals of listed species of the establishments in the surveillance zone
2) To grant derogation for movement from an establishment in the surveillance zone to be moved to a
slaughterhouse within the restricted zone or outside the restricted zone
3) To grant derogation for movement from an establishment outside the surveillance zone to a
slaughterhouse situated in the surveillance zone
4) Clinical examinations and laboratory examination of animals kept in the establishment, including those
animals to be moved
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Summary of sampling procedures
No specific guidelines on sampling procedures for clinical or laboratory examination were found for
the 14th scenario in EU legislation.
Pursuant Art 38 of the Directive 2003/85: ‘1. Member States shall ensure that animals of
susceptible species shall not be removed from holdings within the surveillance zone. 2. By way of
derogation, the prohibition provided in paragraph 1 shall not apply to movement of animals for one of
the following purposes: (a) for leading them without coming into contact with animals of susceptible
species of different holdings, to pasture situated within the surveillance zone not earlier than 15 days
after the last outbreak of FMD has been recorded in the protection zone./. . ./ 3. Movements of animals
provided for in paragraph 2(a) shall be authorised by the competent authority only after an
examination by an official veterinarian of all the animals of susceptible species on the holding,
including testing samples taken in accordance with /. . .’
Assessment
Animals in a surveillance zone, for which a specific derogation has been granted to be moved to
pastures, should be subjected to clinical surveillance, including laboratory examinations.
Sampling procedures for laboratory examination should ensure that the animals do not pose a risk
of transmission with a confidence level of 95%.
Animals of the holding that are negative at the clinical examination and are negative according to
procedures described in Section 4.1.1.2 do pose negligible risk of transmission of FMD.
Development of new procedures
All the animals in the establishment of origin should be clinically examined before their movement
to pastures, following the procedures described in Section 4.1.1.1. Visual inspection of the herd would
be very helpful to identify animals with lameness, excessive salvation, reluctance to move and those
that are remaining isolated and separated from the herd.
In an establishment where the number of animals is large,, the individual clinical examination of all
the animals may not be feasible; in this case a minimum sample of animals (including all animals to be
moved) should be clinically examined to detect or rule out the presence of animals with clinical signs
with at least 95% confidence, as described in Section 4.1.1.1.
In case clinical signs compatible with FMD are identified, the establishment is considered suspected
and the procedures for the laboratory confirmation that are described in Section 4.1.1.1 should be
followed and any movements should be prohibited.
In addition to clinical examination, the dispatch of animals of listed species for FMD to pastures
situated in the surveillance zone should be done after sampling for laboratory examination, following
the procedures described in Section 4.1.1.2, in order to exclude infected but subclinical animals with a
confidence level of 95%.
4.1.2.5. From an establishment in a surveillance zone to an establishment belonging to
the same supply chain, located in or outside the surveillance zone
The purpose of this section is to assess the effectiveness of disease-specific sampling procedures
based on clinical and/or laboratory examinations of kept ungulates of listed species in order to grant
derogation and allow them to be moved from an establishment in the surveillance zone to an
establishment belonging to the same supply chain, located in or outside the surveillance zone, in order
to complete the production cycle before slaughter. For further details, see Annexes B and C.
• 14th scenario of sampling procedures
• ToR 1.4 in accordance with article 43(5) and article 45(1) of the Delegated Regulation (EU) 2020/687
The following elements of the scenario should be taken into consideration during for the assessment:
1) It concerns kept animals of listed species from establishments located in the surveillance zone
2) To grant derogation for movement from the surveillance zone
3) To be moved to pastures situated within the surveillance zone
4) Clinical examinations and laboratory examination of animals kept in the establishment, including those
animals to be moved
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Summary of sampling procedures
No specific guidelines on sampling procedures for clinical or laboratory were found for the 15th
scenario in EU legislation.
Assessment
Animals in a surveillance zone, for which a specific derogation has been granted to be moved to an
establishment of the same supply chain located in or outside the surveillance zone, should be
subjected to clinical examination, including laboratory examinations.
Sampling procedures for laboratory examination should ensure that the animals do not pose a risk
of transmission with a confidence level of 95%.
Moving animals from a non-affected establishment found negative at the clinical examination and
are negative to laboratory examination, according to procedures described in Sections 4.1.1.1 and
4.1.1.2 minimise the risk of FMDV transmission.
Development of new procedures
All the animals in the establishment of origin should be clinically examined before their movement
to an establishment belonging to the same supply chain, following the procedures described in
Section 4.1.1.1. Visual inspection of the herd would be very helpful to identify animals with lameness,
excessive salvation, reluctance to move and those that are remaining isolated and separated from the
herd.
In an establishment where the number of animals is large, the individual clinical examination of all
the animals may not be feasible; in this case a minimum sample of animals (including all animals to be
moved) should be clinically examined to detect or rule out the presence of animals with clinical signs
with at least 95% confidence, as described in Section 4.1.1.1.
In case clinical signs compatible with FMD are identified, the establishment is considered suspected
and the procedures for the laboratory confirmation as described in Section 4.1.1.1 should be followed
and any movements should be prohibited.
The dispatch of animals of the listed species for FMD to an establishment belonging to the same
supply chain should be done after sampling for laboratory examination, following the procedures
described in Section 4.1.1.2, in order to exclude infected but subclinical animals with a confidence level
of 95%.
4.1.2.6. From an establishment located in the restricted zone to move within the
restricted zone when restriction measures are maintained beyond the period set
out in Annex XI of the Delegated Regulation
The purpose of this section is to assess the effectiveness of disease-specific sampling procedures
based on clinical and/or laboratory examinations of the animals of an establishment located in the
restricted zone of an outbreak in order to allow their move within the restricted zone, when restriction
measures are maintained beyond the period set out in Annex XI of the Delegated Regulation. For
further details, see Annexes B and C.
• 15th scenario of sampling procedures
• ToR 1.4 in accordance with article 43(5) and article 45(2) of the Delegated Regulation (EU) 2020/687
The following elements of the scenario should be taken into consideration during for the assessment:
1) It concerns the surveillance zone
2) Grant derogation for movement of kept animals of listed species from the surveillance zone
3) To be moved to an establishment belonging to the same supply chain, located in or outside the
surveillance zone, to complete the production cycle before slaughter
4) Clinical examinations and laboratory examination of animals kept in the establishment, including those
animals to be moved
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Summary of sampling procedures
No specific guidelines on sampling procedures for clinical or laboratory examination were found for
the 18th scenario.
Assessment
Animals in the restricted zone, for which a specific derogation has been granted for movement
within the restricted zone, should be subjected to clinical examination; if they are not immediately
slaughtered, they should also be sampled for laboratory examinations.
Sampling procedures for laboratory examination should ensure that the animals do not pose a risk
of transmission with a confidence level of 95%.
Moving animals from non-affected establishments that are negative at the clinical examination and
are negative to laboratory examination, according to the procedures described in Sections 4.1.1.1 and
4.1.1.2 minimise the risk of FMDV transmission.
Development of new procedures
Sampling procedures should be implemented as described in Sections 4.1.2.1, 4.1.2.3, 4.1.2.4 and
4.1.2.5.
4.1.3. Assessment of sampling procedures for repopulation purposes
4.1.3.1. For the animals that are kept for the repopulation prior to their introduction
The purpose of this section is to assess the effectiveness of disease-specific sampling procedures
based on laboratory examinations of the animals that are kept for the repopulation prior to their
introduction to rule out the presence of the disease. For further details, see Annexes B and C.
Summary of sampling procedures
No specific guidelines on sampling procedures for laboratory examination were found for the 19th
scenario.
• 19th scenario of sampling procedures
• ToR 1.5 in accordance with article 59(2) of the Delegated Regulation (EU) 2020/687
The following elements of the scenario should be taken into consideration during for the assessment:
1) It concerns the repopulation of a previously affected establishment
2) Animals intended to repopulation shall be sampled prior to their introduction into the establishment of
destination
3) The samples shall be collected from a representative number of animals to be introduced of each
consignment from each establishment or from a representative number of animals of each
consignment (if animals are all to be introduced at different times or from different establishments of
origin)
4) The purpose of sampling procedures is to rule out the presence of the disease
• 18th scenario of sampling procedures
• ToR 1.4 in accordance with article 56(1) of the Delegated Regulation (EU) 2020/687
The following elements of the scenario should be taken into consideration during for the assessment:
1) It concerns the restricted zone when restriction measures are maintained beyond the period set out in
Annex XI
2) To grant derogation for movement of kept animals of listed species from an establishment within the
restricted zone
3) Clinical examinations and laboratory examination of animals kept in the establishment, including those
animals to be moved
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Assessment
For animals kept for repopulation, clinical examination and sampling should be used as standard
procedures to ensure that the animals do not pose a risk of FMD transmission. For animals that are
introduced from disease free areas outside the restricted zone, sampling can be omitted because they
have not been exposed to virus before entry and, consequently, can only produce a negative test
result.
Moving animals from non-affected establishments that are negative at the clinical examination and
found negative to laboratory examination, according to the procedures described in Section 4.1.1.1,
minimise the risk of FMDV transmission.
Development of new procedures
Animals intended for repopulation should be subjected to clinical examinations.
In an establishment where the number of animals is large, the individual clinical examination of all
the animals may not be feasible; in this case a minimum sample of animals (including all animals to be
moved) should be clinically examined to detect or rule out the presence of animals with clinical signs
with at least 95% confidence, as described in Section 4.1.1.1.
In case clinical signs compatible with FMD are identified, the establishment is considered suspected
and the procedures for the laboratory confirmation as described in Section 4.1.1.1 should be followed.
The animals intended for the repopulation, even if clinically healthy, should not be dispatched.
If animals are sourced from restricted areas, all the animals in the establishment of origin should be
sampled. Sampling procedures for laboratory examination should ensure that the animals do not pose
a risk of transmission at a confidence level of 95%. Laboratory examinations should be in accordance
to the procedures described in Section 4.1.1.2.
In case the animals originate from establishments located in free areas, there is no need for
laboratory examination if there are no other reasons based on the authorities’ risk assessment to
recommend it (e.g. epidemiological link with an affected establishment or with an affected or high-risk
area). Clinical examination as described above would be enough.
4.1.3.2. In the event of unusual mortalities or clinical signs being notified during the
repopulation
The purpose of this section is to assess the effectiveness of disease-specific sampling procedures
based on laboratory examinations of the animals that have been repopulated, in the event of unusual
mortalities or clinical signs being notified during the repopulation; to rule out the presence of the
disease. For further details, see Annexes B and C.
Summary of sampling procedures
No specific guidelines on sampling procedures for laboratory examination were found for the 20th
scenario.
Assessment
In the case of unusual mortalities or clinical signs compatible with FMD notified during the
repopulation, it is important to rule out the presence of the disease.
Development of new procedures
In the event of animals with clinical signs compatible with FMD, as they have been described in
Section 4.1.1.1, being identified in an establishment during the repopulation, the establishment is
• 20th scenario of sampling procedures
• ToR 1.5 in accordance with article 59(9) of the Delegated Regulation (EU) 2020/687
The following elements of the scenario should be taken into consideration during for the assessment:
1) It concerns the repopulated establishment
2) Unusual mortalities or clinical signs during the repopulation
3) The official veterinarians shall without delay collect samples for laboratory examination
4) The purpose of sampling procedures is to rule out the presence of the disease
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considered suspected. The repopulation should be stopped and the procedures for the laboratory
confirmation as described in Section 4.1.1.1 should be followed.
In addition, the establishments from where the suspected animals originated from, should be
considered as suspected; the procedures described in Section 4.1.1.1 should be followed as well.
4.1.3.3. For animals that have been repopulated
The purpose of this section is to assess the effectiveness of disease-specific sampling procedures
based on laboratory examinations of the animals that have been repopulated, on the last day of the
monitoring period calculated forward from the date on which the animals were placed in the
repopulated establishment. In case the repopulation takes place in several days, the monitoring period
will be calculated forward from the last day in which the last animal is introduced in the establishment.
For further details, see Annexes B and C.
Summary of sampling procedures
Council Directive 2003/85/EC, Annex V, 1.3: ‘Irrespective of the type of farming practised on the
holding, re-introduction must conform with the following procedures:
1.3.1 animals must be introduced in all units and buildings of the holding involved;
1.3.2 in the case of a holding consisting of more than one unit or building, re-introduction is not
necessary for every unit or building at the same time. However, no animals of species susceptible to
foot-and-mouth disease may leave the holding until all the re-introduced animals in all units and
buildings have fulfilled all restocking procedures.
1.3.3 animals must be subjected to clinical inspection every three days for the first 14 days
following the introduction;
1.3.4 during the period from 15 to 28 days after re-introduction, animals are to be subjected to
clinical inspection once every week;
1.3.5 not earlier than 28 days after the last re-introduction, all animals must be clinically examined
and samples for testing for the presence of antibody against foot-and-mouth disease virus shall be
taken in accordance with the requirements of point 2.2 of Annex III;
1.4 The restocking procedure shall be considered completed when the measures provided for in
point 1.3.5 have been completed with negative results.’
Assessment
During the repopulation of an establishment previously affected by FMD, there is still a risk of re-
introduction of the disease with the new animals being infected either at the establishment of origin or
during their transport, and a risk of re-emergence of the disease if the new animals are infected after
their arrival at the establishment of destination. The animals that have been used for the repopulation
should be submitted to thorough clinical and laboratory examination in order to rule out the presence
of the disease.
Development of new procedures
Animals must be subjected to clinical inspection at least every three days for the first 14 days
following the introduction, and weekly from 15 to at least 21 days (monitoring period as defined in the
Delegated Regulation) after re-introduction. The last day of the monitoring period following the latest
day of animals’ introduction, all the animals should be subjected to thorough clinical examination as
described in Section 4.1.1.1 and should be sampled for laboratory examination in accordance to the
procedures described in Section 4.1.1.2.
In an establishment where the number of animals is large, the individual clinical examination of all
the animals may not be feasible; in this case a minimum sample of animals (including all animals to be
• 21st scenario of sampling procedures
• ToR 1.5 in accordance with article 59(5) of the Delegated Regulation (EU) 2020/687
The following elements of the scenario should be taken into consideration during for the assessment:
1) It concerns the repopulated establishment
2) Animals that have been used for repopulation
3) The purpose of sampling procedures is to rule out the presence of the disease
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moved) should be clinically examined, to detect or rule out the presence of animals with clinical signs
with at least 95% confidence, as described in Section 4.1.1.1.
If clinical signs are identified, then the procedures for the laboratory confirmation that are
described in Section 4.1.1.1 should be followed.
4.2. Assessment of the length of the monitoring period
The concept of the monitoring period has been introduced as a management tool for the
investigation and control of suspected and confirmed outbreaks of Category A diseases in terrestrial
animals. This tool aims to standardise the methodology by which relevant authorities respond to
suspected and confirmed cases of these diseases. In this regard, a disease-specific monitoring period
was set for each of the 14 diseases included in the Category A list. Throughout the EU legislation, the
monitoring period is used as an aid in the control of these diseases, although the specific purpose in
which the monitoring period is used varies depending on the articles of the legislation.
The length of the monitoring period for each disease is set out in Annex II of the Commission
Delegated Regulation (EU) 2020/687 supplementing the rules laid down in Part III of Regulation (EU)
2016/429 (Animal Health Law).
Annex D in this Opinion describes the seven scenarios, for which an assessment of the length of
the monitoring period for FMD had been requested.
For the assessment of this ToR, the methodology described in Section 2.3 of the Technical Report
published by EFSA (EFSA, 2020) was followed. In essence, in order to assess the length of the
monitoring period, the purpose of this monitoring period for each of the scenarios was ascertained.
To answer all scenarios except Scenario 5, an extensive literature search (ELS) on the average,
shortest and longest period of time between the earliest point of infection of an animal with FMDV,
and the time of reporting of a suspicion by the competent authority, was carried out. The time period
between reporting of a suspicion and the notification of the disease was also assessed. Several
outcomes were designed for the ELS as shown in the protocol, and the results are presented below.
To answer Scenario 5 a literature search was conducted by EFSA on the seroconversion period, as




A search was carried out identifying 2,305 references published after 1/1/2000. Among these
references, 15 were selected to be included in the qualitative review. The full selection process is
displayed in Figure 5.
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The majority of the references reported dates instead of periods (10 references out of 15);
therefore, the dates were used to calculate the different periods of interest.
Table 6 provides an overview of the data that were extracted for the main outcome of interest, i.e.
the period between the earliest point of infection and the suspicion report.







point of infection and
suspicion report (days)
Gibbens et al. (2001) United Kingdom 2001 Pig 21(1)




Alexandersen et al. (2003a) United Kingdom 2001 Cattle 6–26(2)
EuFMD (2001) France 2001 Cattle 14(3)
Bouma et al. (2003) Netherlands 2001 Goat 19(4)
Ryan et al. (2008) United Kingdom 2007 Cattle 8–13(5)
DEFRA (2007b) United Kingdom 2007 Cattle 7–20(2)
DEFRA (2007a) United Kingdom 2007 Cattle 6–18; 11–23(2)
EFSA AHAW Panel (2012) Bulgaria 2011 Cattle 6–18(2)
Rautureau et al. (2012) France NA Cattle, pig, sheep
and goat
6–14(6)
(1): Average period based on date of first infection determined retrospectively through the examination of lesions.
(2): Most likely window (min-max) based on date of first infection determined retrospectively through the examination of lesions.
(3): The ‘shortest’ probable period based on the date of slaughter of the UK imported sheep that most likely infected the cattle
neighbouring farm.
(4): Suspicion was made on goats, contaminated by imported Irish calves. The period is based on the import date of the calves,
which were infected during a stopover in Mayenne (France).
(5): Min–max based on date of first infection determined retrospectively through the examination of lesions and several
hypotheses; the most likely source is a release of virus from the Pirbright Institute site.
Figure 5: PRISMA diagram FMD monitoring period ELS
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The available information on the main outcome of interest, i.e. the period between the earliest
point of infection and the suspicion report, is described in Table 6.
The first outbreak during the 2001 epidemic in the United Kingdom (Ferguson et al., 2001) was
suspected following an ante-mortem inspection in an Essex abattoir of pigs presenting signs of acute
infection. Three days had occurred between the arrival of the pigs at the abattoir and the suspicion
report by the Official Veterinary Surgeon (Gibbens et al., 2001). As a result of backward contact
tracing, a veterinary inspection found FMD on a swill-fed pig fattening unit that was identified as the
most likely source of the abattoir outbreak. Epidemiological investigations revealed that 21 days had
elapsed between the first infection and the confirmation in these premises (Gibbens et al., 2001;
Sutmoller et al., 2003; McLaws, 2005).
The longest period retrieved was 26 days and was reported in the context of a cattle outbreak
during the 2001 epidemic in the United Kingdom (Alexandersen et al., 2003a). This is the upper value
of the time window that was calculated by adding the estimated age (12 days) of the oldest lesion
observed at suspicion, to the theoretical incubation period (2–14 days) (OIE, 2013).
Only one extracted value out of fourteen concerned sheep (Ferguson et al., 2001) or goat (Bouma
et al., 2003) or pig (Gibbens et al. (2001) outbreaks, and it is therefore difficult to draw conclusions in
these species.
Based on the species-specific data presented in Table 6, the average, shortest and longest period
was calculated separately for cattle, pigs and small ruminants (i.e. values referring to multiple species
were not used):
Cattle (n = 8):
• Average period = 13 days
• Shortest period = 6 days
• Longest period = 26 days
Pigs (n = 1):
• Average/Shortest/Longest period = 21 days
Small ruminants (n = 2):
• Average period = 14 days
• Shortest period = 9.5 days
• Longest period = 19 days
Based on the results presented in Table 6, it can be observed that the current Monitoring Period
(21 days) is longer or equal to the average period obtained in the ELS for all species. However, it must
be noted that only one reference was available for sheep, goats and pigs. Considering the fact that
clinical forms of FMD are generally less severe in small ruminants than in cattle (OIE, 2013), these
results might not be representative of sheep or goat outbreaks that are expected to be associated with
longer reporting periods compared with cattle outbreaks.
Seroconversion in animals
Several publications describing experimental infection with FMDV were consulted (Tables 7–9) and
the time of seroconversion after infection/inoculation and contact was retrieved from the serological
results described. Nevertheless, these studies were not designed to estimate the time between
infection and seroconversion (first time when antibodies can be detected) and they can only provide
an estimation.
In experimental studies (Table 7), where non-vaccinated naive animals were infected directly with
FMDV through inoculation of the virus(es) via intradermal lingual route or inoculation in the coronary
band, the latest day of seroconversion was: i) 10 dpi by VNT, ii) 8 dpi by SPCE, iii) 5 dpi by LPBE and
iv) 15 dpi by NSP ELISA (Cedi, PrioCHECK).
(6): Median range obtained from simulated epidemics based on an FMD SLIJR transmission model, the general level of actor
awareness, passive surveillance network type, FMDV strain virulence and district. The transmission and the detection
parameters were estimated using expert opinion and the results of a meta-analysis of data from experimental infections. As
this value is not species-specific, it was further excluded from the analysis.
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In experimental studies (Table 8) where non-vaccinated naive animals were infected through direct
contact with animals infected with FMDV serotype O, the latest day of seroconversion was: i) 20 dpc
by VNT, ii) 20 dpc by SPCE, iii) 14 dpc iELISA, iv) 4 dpc by LPBE, v)16–28 dpc by NSP ELISA
commercial tests. It should be mentioned that the time of seroconversion has been calculated
forwards from the day when the animals joined the infected animals and not from the day of infection,
which is not known. This fact may explain the delay in detection of seroconversion in these
experiments.
Table 7: Latest day seroconversion started as retrieved from publications describing experimental
studies where FMDV was inoculated directly into non-vaccinated naive animals. The















VNT (CO ≥ 1/45) Cattle IDL O 7 Paiba et al. (2004)
VNT Cattle IDL A, O, SAT 10 Parida, personal
communication,
20215
VNT (CO ≥ 1/45) Sheep Coronary band O 10 Paiba et al. (2004)
VNT Sheep  IDL
 Coronary band




VNT (titre ≥ 40) Pigs IDL O + ASFV 11 Douglas et al.
(1993)
SPCE (CO ≥ 60
PI)
Cattle IDL O 5 Paiba et al. (2004)
SPCE (CO ≥ 60
PI)
Sheep Coronary band O 8 Paiba et al. (2004)
LPBE (CO ≥ 50%
PB at serum
dilution 1/10)
Cattle IDL A, O, C 5 O’Donnell et al.
(1996)
NSP ELISA
(Cedi) (CO ≥ 50
PI)











Sheep – IDL +Coronary band 10
Goats – IDL
– IDL +Coronary band
10
Goats – Coronary band 15
dpi: days post infection inoculation; IDL: Intradermal lingual route; LPBE: Liquid-phase blocking ELISA; NSP: Non-Structural
Protein Antibody Test; SPCE: Solid-phase Competition ELISA; VNT: Virus Neutralisation Test; PI: percentage inhibition; PB:
Percentage Blocking; CO: cut-off.
(1): Between 9 and 15 dpi no samples were taken.
(2): Sampling every 5 days.
5 Personal commutation with Dr Parida Satya from Pirbright Institute (World Reference Laboratory for FMD) on unpublished data.
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In experiments where vaccinated animals against FMDV, were infected through direct contact with
animals infected with FMDV serotype O, the latest day of seroconversion identified for each laboratory
methods is presented in Table 9, and, as can be observed, there is a delay in detecting a
seroconversion compared to non-vaccinated animals (Table 8). For these experiments, the effect of the
vaccination on the immune system of the animals should be considered in the interpretation of the
results. It should be also mentioned that the time of seroconversion has been calculated forwards from
the day when the animals joined the infected animals and not from the day of infection, which was
not known.
Table 8: The latest day of seroconversion (when the last animal of the study seroconverted) in the
experimental studies where non-vaccinated, naive animals were infected through direct







VNT Cattle 7 Cox et al. (2005)
VNT (CO ≥ 1/45) Cattle 20 Paiba et al. (2004)
VNT (CO ≥ 1/45) Sheep 10 Paiba et al. (2004)
SPCE (CO ≥ 60 PI) Cattle 12 Parida et al. (2005)
SPCE (CO ≥ 60 PI) Cattle 20 Paiba et al. (2004)
SPCE (CO ≥ 60 PI) Sheep 8 Paiba et al. (2004)
SPCE (CO ≥ 60 PI) Pig 9 Paiba et al. (2004)
Indirect 2B peptide ELISA (CO: OD > 0.67) Cattle 14 Parida et al. (2005)
LPBE(CO = 50% PB at serum dilution 1/40) Pigs 4 Alexandersen et al. (2001)
NSP ELISA (commercial tests: UBI, Cedi,




Parida et al. (2005)
NSP ELISA (Cedi) and in house ELISA Sheep 15(1) Madhanmohan et al. (2010)
Goats 10(1)
dpc: days post contact with infected animals; LPBE: Liquid-phase blocking ELISA; NSP: Non-Structural Protein Antibody Test;
SPCE: Solid-phase Competition ELISA; VNT: Virus Neutralisation Test; PI: Percentage Inhibition; PB: Percentage Blocking; OD:
optical density; CO: cut-off.
(1): Sampling every 5 days.
Table 9: Latest day of seroconversion (when the last animal of the study seroconverted) in the
experimental studies where vaccinated animals were infected through direct contact with







VNT (CO ≥ 1/45) Cattle 16 Parida et al. (2005)
Indirect 2B peptide ELISA (CO: OD > 0.79) Cattle 42 Parida et al. (2005)
NSP ELISA (commercial tests: UBI, Cedi,




Parida et al. (2005)
NSP ELISA (commercial tests: UBI, Cedi,




Parida et al. (2005)
NSP ELISA (Cedi) and in house NSP ELISA Sheep 28(1) Madhanmohan
et al. (2010)Goats 35(2)
dpc: days post contact with infected animals; IDL: Intradermal lingual route; LPBE: Liquid-phase blocking ELISA; NSP: Non-
structural protein antibody test; SPCE: Solid-phase competition ELISA; VNT: Virus neutralisation test; OD: Optical density.
(1): Previous negative sampling in 21 dpc.
(2): Previous negative sampling in 28 dpc.
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In the experimental studies mentioned above, the antibodies remained detectable until the end of
the observation period of the trial or until the animals were euthanised. The longest period of antibody
detection found in experimental studies was 565 dpi, with LPBE in cattle serum as reported by
(O’Donnell et al., 1996).
4.2.2. Assessment
Considering the results presented above, an assessment of the effectiveness of the monitoring
period for FMD, depending on the purpose of that period in the different scenarios shown in Annex D,
was carried out. For FMD, the length of the monitoring period as defined in Annex II of the Delegated
Regulation is 21 days.
Scenarios 1, 2 and 3
For the first three scenarios, the main purpose of the use of the monitoring period is to be able to
carry out a full epidemiological investigation (i.e. in scenarios 1 and 2, at the time of the suspicion and
confirmation, respectively), or part of the epidemiological investigation (i.e. scenario 3, where the aim
is to identify any possible epidemiological links between the affected establishment and any separated
non-affected epidemiological units).
The length of the monitoring period should then dictate how far, backward or forward, the activities
related to tracing (and other activities needed during an epidemiological investigation) should go
(checks for production records, animal movement records, etc.). This monitoring period is the time,
where the infection could have been present and remains undetected in an establishment, and due to
the regular activities carried out in this establishment, could have spread to other epidemiological
units.
In the case of scenario 3, if no epidemiological links between the establishment that has been
confirmed positive and the other epidemiological units are found during the investigation (and only if
other conditions described in the legislation are met), a derogation from killing the animals in the
separated non-affected epidemiological units could be granted.
1st scenario of monitoring period
• ToR 2 in accordance with article 8 and Annex II of the Delegated Regulation (EU) 2020/687
• Article 57 of the Regulation (EU) 2016/429
• Aim: to assess the effectiveness of the length of the Monitoring Period, as the time period calculated
backwards from the date of the notification of the suspicion of a category A disease in an establishment
with kept animals of listed species, for the purposes of the epidemiological enquiry in the event of a
suspicion of a FMD outbreak
2nd scenario of monitoring period
• ToR 2 in accordance with article 17(2) and Annex II of the Delegated Regulation (EU) 2020/687
• Article 57 of the Regulation (EU) 2016/429
• Aim: to assess the effectiveness of the length of the Monitoring Period, as the time period calculated
backwards from the date of notification of the suspicion of a category A disease in an establishment with
kept animals of listed species, for the purposes of the epidemiological enquiry in the event of
confirmation of a FMD outbreak
3rd scenario of monitoring period
• ToR 2 in accordance with article 13(b) and Annex II of the Delegated Regulation (EU) 2020/687
• Aim: to assess the effectiveness of the length of the Monitoring Period, as the time period calculated
backwards from the date of confirmation of a FMD outbreak in an epidemiological unit in which the
disease has not been confirmed, in order to provide derogations from killing the animals in this unit, if
this unit has been completely separated, and handled by different personnel during this monitoring
period
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The period of time the disease could have been present and undetected in an establishment
equates then to the time period between the entry of FMD into the establishment and the reporting of
the suspicion. Once the suspicion has been officially reported, control measures are implemented and
further spread should in this way be prevented.
Based on the ELS carried out and presented above, the average length of the time between
infection and the suspicion report was estimated as 13 days in cattle, 21 in pigs and 14 days in small
ruminants, based on articles where an epidemiological investigation was carried out. Although the
monitoring period defined in the Delegated Regulation is longer than the average calculated for all
animal species using this methodology, it is important to take into account that when the disease is
first introduced in an area, detection may be late. This should be considered when carrying out an
epidemiological investigation in the index case (first affected establishments) in an area.
The length of the monitoring period of 21 days as defined in the Delegated Regulation is therefore
considered effective, except for the first affected establishments detected in an area, where a
monitoring period of 26 days, (the longest period found in the ELS) is recommended.
Scenario 4
The main purpose of the monitoring period in scenario 4 is to ensure that certain products or
materials, likely to spread the disease, that have been produced in a non-affected establishment
located in the protection zone of an affected establishment, can be moved safely and without posing a
risk of disease spread. In this scenario, and in contrast with the previous three scenarios, the
establishment of concern is neither a suspected nor an affected establishment, but restrictions are still
in place, for establishments in the protection zone.
For the assessment of this scenario, we assume that the earliest plausible point of infection of
these products or materials in the establishment of concern would be the earliest plausible point of
infection of the establishment that originated the protection zone. If these products have been
obtained or produced before the earliest point of infection of the affected establishment, then they
could be exempted from prohibitions to be moved, as long as other conditions specified in the
legislation are met (e.g. the products must have been clearly separated during the production process,
storage and transport, from products not eligible for dispatch outside the restricted zone).
As the disease has already been detected in the area, and high awareness is expected, the length
of the monitoring period is considered effective in this scenario.
Scenario 5
The aim of the monitoring period is to ensure that semen from animals in the non-affected
establishments (located in a protection or surveillance zone) that has been collected and frozen after
the earliest time of infection of the affected establishment that originated the protection zone, is safe
to be moved without posing a risk of disease spread. In this scenario, EFSA is requested to assess the
4th scenario of monitoring period
• ToR 2 in accordance with article 27(3)c and Annex II of the Delegated Regulation (EU) 2020/687
• Aim: to assess the effectiveness of the length of the Monitoring Period, as the time period calculated
backwards from the date of notification of the suspicion of the FMD outbreak in the protection zone.
Products or other materials likely to spread the disease, must had been obtained or produced, before
this time period in order to be exempted from prohibitions of movements
5th scenario of monitoring period
• ToR 2 in accordance with article 32 (c), article 48(c) and Annex II of the Delegated Regulation (EU)
2020/687
• The purpose of this Section is to assess the effectiveness of the length of the Monitoring Period, as the
time period calculated forwards from the date of semen collection from animals of listed species kept in
approved germinal product establishments in the protection or in the surveillance zone, to prove that the
donor animal has tested favourable on a sample taken not earlier than 7 days after the monitoring
period
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length of time, after the semen was taken, when the animal should be tested in order to allow that
semen to be moved. Here, it is assumed that the earliest point of infection of the animal would be on,
or after the earliest point of infection of the affected establishment that originated the protection zone,
and the latest date the semen could have become contaminated would be the date the semen was
collected.
FMDV can be detected in high titres in the semen of infected animals (EFSA AHAW Panel, 2006),
and the longest reported detection time in frozen semen (–50°C, with or without extenders) is 320
days (Cottral et al., 1968). A more recent study conducted in an affected cattle farm by Sharma et al.
(2012) showed that semen from infected bulls was found positive by mPCR 5 months after infection
but was negative after 8 months. Based on the EFSA AHAW Panel (2006), the probability of infection
through artificial insemination (AI) with contaminated semen is higher than negligible and may be very
high.
In this scenario, where the semen might have been contaminated the latest at the date of
collection from an infected donor without clinical signs or with mild clinical signs that remained
unnoticed, a serological test would indicate if the donor has ever been exposed to FMDV and therefore
if the semen could be contaminated.
Based on the results presented in Section 4.2.1 in relation to the seroconversion in non-vaccinated
naive animals, the latest date of seroconversion was identified as 15 days post infection by NSP ELISA
(Parida, personal communication, 20215; Madhanmohan et al., 2020).
The latest date of seroconversion for non-vaccinated, naive animals infected through contact with
already infected animals was identified as 28 days post contact by NSP ELISA as reported by Parida
et al. (2005).
Consequently, and based on the results of the publications, sampling the animals at least 28 (21 + 7)
days after semen collection as foreseen in the Delegated Regulation is considered effective to detect
antibodies with several laboratory methods, given that the infection may have occurred at the latest on
the day of semen collection.
Scenarios 6 and 7
In scenarios 6 and 7, the monitoring period is used in the context of repopulation.
In scenario 6, the monitoring period is used to ensure that the repopulation process is not put at
risk due to the disease still being present unknowingly in establishments within the surrounding area of
the establishment to be repopulated (if an establishment tested positive to FMDV within a distance
equal or lower to the radius of the surveillance zone, the repopulation process could not take place).
Repopulation can only take place after a period equal to the monitoring period has elapsed, since
the final cleaning, and disinfection of the affected establishment.
In this regard, the number of days of the monitoring period for FMD, counted from the day of the
final cleaning and disinfection, must ensure enough time for any potentially affected surrounding
establishment to be reported as a suspicion. Considering the results presented in Section 4.1.2, and
taking into account that a high level of awareness is expected due to the disease having been present
in the area, the EFSA AHAW Panel considers the existing length of the monitoring period (21 days)
7th scenario of monitoring period
• ToR 2 in accordance with article 59 (4) and Annex II of the Delegated Regulation (EU) 2020/687
• Aim: to assess the effectiveness of the length of the Monitoring Period, as the time period calculated
forward from the date the first animal was introduced for the purpose of repopulation, during this
monitoring period, all animals of the listed species intended for repopulation should be introduced
6th scenario of monitoring period
• ToR 2 in accordance with article 57 (1) and Annex II of the Delegated Regulation (EU) 2020/687
• Aim: to assess the effectiveness of the length of the Monitoring Period, as the time period calculated
forward from the date of the final cleaning and disinfection in an affected establishment, after which the
repopulation of the establishment may be allowed by the competent authority (assuming relevant control
of insects and rodents was carried out)
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effective, as it would allow for the identification of any potentially affected establishment in the
surrounding area prior to the repopulation taking place.
In scenario 7, the monitoring period must be counted forwards from the date on which the first
animal is introduced into the establishment to be repopulated, with all the animals intended for
repopulation of this establishment being introduced within the length of time of this monitoring period.
The aim of the monitoring period in this scenario is to ensure the early detection of any potentially
recently infected animal intended for repopulation once all animals have been moved into the
repopulated establishment. Although the preferred option is that all animals are introduced into the
establishment to be repopulated at the same time, this is not always feasible. The first clinical and
laboratory sampling of the repopulated animals takes place once all the animals are in situ. By
restricting the period of time during which animals may be introduced into the establishment, the
period of time during which the disease could be unknowingly spreading within the establishment is
reduced. Assuming that the latest point of infection of an animal introduced into the repopulated
establishment is the day when it is moved, and considering that the average length of time to
detection is 13 days in cattle, 12 in pigs and 14 days in sheep and goats, it would be likely that some
clinical signs would be present in animals if this visit is carried out 21 days after the last introduction.
In this scenario, using the average length of time to detection would be justified as a high awareness
will exist during the examination of the animals at the first visit. The EFSA AHAW Panel considers the
existing length of the monitoring period (21 days) effective, as it would allow for early detection of
potentially infected animal at the first visit following re-stocking.
4.3. Assessment of the minimum radius and time periods of the
protection and surveillance zones set in place subsequent to an
FMD outbreak
4.3.1. Assessment of the minimum radius
The purpose of this section is to assess the effectiveness to control the spread of FMDV of the
minimum radius of the protection and surveillance zones as set out in Annex V of the Delegated
Regulation for FMD. According to this regulation, the minimum radius for the protection and
surveillance zones for FMD is 3 km and 10 km, respectively (Annex V of the Delegated Regulation).
Results
To address this request, transmission kernels (Table 10 and Figure 6) have been used to analyse
outbreak data for four epidemics of FMD (Table 10), all of which were caused by strains of FMDV serotype
O. Three different functional forms for the kernel were used (Table 10). The fitted kernels are consistent in
shape across the epidemics, with a substantial drop off in the kernel beyond 3 km (Figure 6).





k(r) ¼ 1þ r
d0
 a Japan 2010 0.58 2.47 Hayama et al. (2013)†
UK 2001 1.32 (1.10, 1.55) 2.67 (2.56, 2.77) Chis Ster and Ferguson
(2007)†
UK 2001 1.38 (1.33, 1.44) 2.84 (2.77, 2.93) Chis Ster et al. (2009)†
UK 2001 1.92 (1.41, 2.45) 3.1 (2.8, 3.3) Chis Ster et al. (2012)†
UK 2001 1.84 (1.62, 2.05) 4.17 (3.93, 4.40) Schley et al. (2009)
k(r) ¼ 1þ r
d0
 a 1 NL 2001 0.9 (0.4, 2.1) 2.3 (2.0, 2.8) Backer et al. (2012)
NL 2001 1.22 (0.67, 3.35) 2.8 (2.3, 4.1) Boender et al. (2010)
UK 2001 1 3 Werkman et al. (2016)







( UK 2001 0.72 (0.44, 1.14) 1.66 (1.62, 1.70) Deardon et al. (2010)
*: 95% confidence or credible intervals are shown in brackets if they were reported in the original reference.
†: These studies considered several kernels or models; kernel parameters for the best-fitting one, are included here.
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For each kernel in Table 10, the probability of transmission beyond given distances (if transmission
was to occur from an affected establishment) was computed using the estimates, lower and upper
95% confidence limits, including distances beyond the proposed radius for the protection and
surveillance zones (3 km and 10 km, respectively) (Figure 6). In addition, the distances at which a
threshold probability of transmission beyond that distance is reached were also calculated for each
kernel using the estimates, lower and upper 95% confidence limits (Figure 7). The corresponding
values computed using the estimates are summarised in Table 12.
Figure 6: Transmission kernels for FMDV
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Figure 7: Assessment of the radius of the protection and surveillance zone for FMDV. The top panel
shows the probability of transmission beyond a given distance (if transmission were to
occur from an affected establishment) computed using the estimates (blue circles) and the
lower and upper 95% confidence limits (error bars) for each kernel (and in the same order
as) in Table 10. The thick black line indicates the median probability for all kernels. The
black dotted lines indicate threshold probabilities of 0.05 and 0.01. The bottom panel
shows the distances at which a threshold probability of transmission beyond that distance is
reached calculated using the estimates (circles) and lower and upper 95% confidence limits
(error bars) for each kernel. The thick black line indicates the median distance for all
kernels. The black dotted lines indicate distances of 3 and 10 km (i.e. the proposed radius
of the protection and surveillance zones, respectively)
Table 11: Probability of transmission of foot and mouth disease virus beyond different distances
(km) from an affected establishment point based on the kernels of Table 10 and Figure 6
Distance (km) of transmission from affected establishment
3 5 10 15 20 25 50
Median 4.8% 1.7% 0.3% 0.1% 0.1% < 0.1% < 0.1%
Minimum 1.1% 0.4% < 0.1% < 0.1% < 0.1% < 0.1% < 0.1%
Maximum 9.4% 4.0% 1.3% 0.7% 0.4% 0.3% 0.1%
Table 12: Distances (km) at which the probability of transmission of foot and mouth disease virus
beyond that distance reaches a threshold level point based on the kernels of Table 10
and Figure 6
Threshold probability of transmission beyond certain distances (km)
0.1% 0.5% 1% 5% 10% 20% 50%
Median 15.1 8.2 6.2 2.9 2.1 1.4 0.6
Minimum 7.8 4.4 3.2 1.4 0.9 0.5 0.2
Maximum 46.2 17.5 11.5 4.4 2.9 2.0 1.2
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Assessment
As seen from Figures 6 and 7, Tables 11 and 12, that the probability of FMD transmission beyond a
certain distance from an affected establishment decreases as the distance increases.
The individual transmission event from one affected establishment to another was estimated using
different distances and different thresholds of the probability of FMD transmission FMD certain
distances.
Table 11 shows that, if transmission occurs, the median probability of transmission of FMD from
one affected establishment beyond 3 km (outside the current protection zone) is 4.8%, while the
maximum probability is 9.4%. Likewise, the median probability of one affected establishment to
transmit FMD to another establishment located beyond 10 km (outside the current surveillance zone)
is 0.3% while the maximum probability is 1.3%.
Based on the median relative probability of transmission from an affected establishment beyond
given distances if transmission occurs, it is concluded that the minimum radius of the protection zone
(3 km) and the surveillance zone (10 km) (as set out in Annex V of the Delegated Regulation for FMD)
are effective assuming a threshold of 95% probability as used in several articles of the AHL. For the
surveillance zone, the expected effectiveness could be increased up to a 99% probability.
Transmission over longer distances cannot be excluded if infected animals are moved outside the
zones.
Based on the estimations of the kernels, the probability of transmission outside the defined zones
decreases as the radius of the zones (distance from the affected establishment) increases. Takin into
consideration the local epidemiological situation, the density of the establishments and the commercial
activities different combinations of radiuses in the protection and the surveillance zones may be
selected to further decrease the spread of the disease.
4.3.2. Assessment of the minimum period
The purpose of this section is to assess the effectiveness to control the spread of FMD of the
minimum periods during which the competent authority should apply the restriction measures in the
protection and surveillance zones as set out in Annexes X and XI for the FMD. The minimum period for
the protection zone is 15 days, while for the surveillance zone is 30 days
To assess the minimum length of time the protection zone and the surveillance zones should be
kept in place, the average (for the protection zones) and the longest (for the surveillance zones)
period between the earliest point of infection and the notification of a suspicion will be used (EFSA,
2020).
Based on the results of the ELS as presented in Table 6 in Section 4.2.1, it follows that the average
time between infection and notification of the suspicion is 13 days in cattle, 12 in pigs and 14 days in
small ruminants. Therefore, the minimum period of 15 days indicated in the Delegated Regulation for
the restriction measures in the protection zone is considered effective to detect effected
establishments and to prevent the movement of infected animals from the protection zone.
In addition, the maximum period between introduction and suspicion is 26 days in cattle, 21 in pigs
and 19 days in small ruminants. Consequently, the minimum period of 30 days indicated in the
Delegated Regulation for the restriction measures in the surveillance zone is considered effective to
detect affected establishments and to prevent the movement of infected animals from the surveillance
zone.
However, it must be noted that only one reference for swine and two for small ruminants (one for
sheep and one for goats) were available from the ELS. Considering the fact that clinical forms of FMD
are generally less severe in small ruminants than in cattle (OIE, 2013), these results might not be
representative of sheep or goat outbreaks that are expected to be associated with longer reporting
periods compared with cattle outbreaks.
4.3.3. Uncertainty analysis
Although several sources of uncertainty were identified during the scientific assessment (see
Annex F), their impact on the outputs of the assessment was not quantified.
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5. Conclusions and Recommendations
Sampling
procedure
Laboratory guidelines based on Council
Directive 2003/85/EC if not stated otherwise
Conclusions Recommendations
ToR 1: In the event of suspicion or confirmation
1st scenario
Section 4.1.1.1 In
the event of a
suspicion of FMD in
an establishment
where animals of the
listed species are
kept
1. Clinical examination: Council Directive 2003/85/
EC: Annex III: ‘1.1. Holdings must undergo clinical
examinations of all animals of susceptible species for
signs or symptoms of foot and mouth disease.
1.2. Special emphasis must be laid on animals which
may have been exposed to foot and mouth disease
virus with a high probability, notably transport from
holdings at risk or close contact to persons or
equipment that had close contact to holdings at risk.
1.3. The clinical examination must take into account
the transmission of foot and mouth disease,
including the incubation period referred to in Article
2(h) and the way in which animals of susceptible
species are kept.
1.4. Relevant records kept on the holding must be
examined in detail with particular regard to data
required for animal health purposes by Community
legislation and, where available, on morbidity,
mortality and abortion, clinical observations, changes
in productivity and feed intake, purchase or sale of
animals, visits of persons likely to be contaminated
and other anamnestically important information.
2. Laboratory examination: Council Directive 2003/
85/EC: Annex III 2.2.: Sampling on holdings: In
holdings where the presence of foot and mouth
disease is suspected but in the absence of clinical
signs, sheep and goats and on recommendation of
the epidemiological team other susceptible species,
should be examined pursuant to a sampling protocol
suitable to detect 5% prevalence with at least 95%
level of confidence.’
Foot and mouth disease (FMD) is
of variable severity between
species, with cattle and pigs
showing obvious signs of illness,
whilst infection can be mild or
subclinical especially in small
ruminants and partially immune
animals.
To detect an outbreak in previously
naive cattle and pig herds with
95% confidence, samples of at
least 3 animals with typical clinical
signs should be submitted to the
lab when using the combined PCR
test (3D-RT-PCR + 50UTR-RT-PCR
performed in parallel). In case of a
single PCR test or antigen ELISA,
samples of 4 animals should be
submitted.
A sample of epithelium of lesions is
preferred for laboratory analysis,
but if not possible, an EDTA-blood
sample can also be used.
To detect an outbreak in previously
naive sheep or goat flocks with
95% confidence, samples of at
least 7 animals with clinical signs
should be submitted to the lab
when using the PCR test. In case
of antigen ELISA, samples of 8
animals should be submitted.
It is recommended to examine as many individual animals
in a suspect cattle or pig herd so that at least 3–4 clinically
suspect animals have been identified for collecting samples
for laboratory analysis that is likely with 95% confidence
that the prevalence of such animals is below 2%.
In a suspect cattle or pig herd, it is recommended to
submit samples from at least 3 animals with clinical signs
to a lab where a combined PCR test is used, or from 4
animals in case a single PCR test or Ag ELISA is used.
It is recommended to examine as many individual animals
in a suspect sheep/goat flock so that at least 7–8 clinically
suspect animals have been identified for collecting samples
for laboratory analysis, or that it is likely with 95%
confidence that the prevalence of such animals is below
2%.
In a suspect sheep/goat flock it is recommended to submit
samples from at least 7 clinically suspect animals to a lab,
where a PCR test is used, or from 9 animals in case Ag
ELISA is used.
In the absence of clinical signs in a sheep/goat flock,
collecting serum samples allowing the detection of a 5%
design prevalence with 95% confidence is recommended.
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the purposes of the
epidemiological
enquiry as referred
to Article 57 of
Regulation (EU)
2016/429 in an FMD
officially confirmed
establishment
Council Directive 2003/85/EC: 2.1.2. To carry out an
epidemiological investigation and where sampling is
carried out in the framework of disease surveillance
after an outbreak, actions shall not commence
before at least 21 days have elapsed since the
elimination of susceptible animals on the infected
holding(s) and the carrying out of preliminary
cleansing and disinfection, unless otherwise provided
for in this Annex.
Epidemiological enquiry
The epidemiological enquiry in an
affected establishment may be
supported by sampling procedures
for the following purposes:
• to estimate the prevalence of
clinical signs within the
affected establishment to
understand how widespread
the infection is within the
establishment and for how
long whenever this is feasible
• to estimate the age of the
lesions providing information
on the most likely time and
pathway of introduction of
FMD into the establishment
and consequently support the
quick tracing of the contacts.
• to identify the virus and
estimate the geographical
origin of the disease.
Preventive Killing
Confirm and rule out the disease
in case of preventing killing will be
based on clinical and laboratory
examination of the animals.
Epidemiological enquiry
• Animals that are still alive or those that are found
dead or were culled should be examined to identify
clinical signs and lesions compatible with FMD. A brief
visual inspection of the mouth and feet of the animals
is sufficient for this purpose and in case that is not
feasible due to a large population, it is recommended
to examine at least 100 animals (allows estimation of
50% prevalence with an accepted error of 10% with
95% confidence). Lesions in those animals first
infected may allow to estimate the length of time the
disease is present in the establishment.
• Additional samples for PCR can be collected in a
confirmed affected establishment to investigate how
widespread the infection is. Sequencing of VP1 can be
helpful to determine the origin of the virus.
Preventive Killing
In case of preventive killing, all animals should be
subjected to clinical examination, and if no cases of
clinically suspects are observed, blood samples should be
collected from a random sample of animals allowing











No specific guidelines on sampling procedures for
clinical or laboratory examination were found for the
3rd scenario.
In an FMD affected establishment,
there might be animals, which are
in the incubation period without
having been detected by
laboratory tests carried out.
Furthermore, among ruminants
some animals may become
‘carriers’ following their exposure,
and this needs to be taken into
Regular clinical examination should be carried out,
preferably every day, to early detect the onset of clinical
signs, for a period of at least the existing monitoring period
of 21 days calculated forwards from the day of
confirmation of the latest case.
All the animals intended for derogation of killing should be
subjected to thorough individual clinical examination to
identify those animals with clinical signs in order to take
samples for the laboratory examination.
Sampling all the animals for laboratory examination, as
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soon as the derogation of killing is applied and
irrespectively of the presence of clinical signs, will enable
to identify also infected animals without clinical signs,
estimate the prevalence of FMD in the establishment and
evaluate the risk.
Sampling for laboratory examination can be repeated at
any time, but the last sampling should be carried out not
earlier than 21 days calculated forwards from the day of
confirmation of the latest case.









No specific guidelines on sampling procedures for
clinical or laboratory examination were found for the
4th scenario.
Council Directive 2003/85/EC: In the Article 2 (a):
‘animal of a susceptible species’ means any domestic
or wild animal of the suborders Ruminantia, Suina
and Tylopoda of the order Artiodactyla. For specific
measures, notably in application of Article 1(2),
Article 15 and Article 85(2), other animals, such as
for example of the order Rodentia or Proboscidae,
may be considered susceptible to foot and mouth
disease in accordance with scientific evidence.
FMDV natural or experimental
infection has been reported in
several species other than the
Artiodactyla and Proboscidea,
although not confirmed by virus
isolation or virus detection in all of
the cases, and without evidence of
their role on the epidemiology
(transmission, persistence) of the
disease in the field.
In some cases, the species
mentioned are not natural
inhabitants of the European
Continent.
The available diagnostic methods
for FMD may not be validated for
these animals.
If clinical signs occur in animals of non-listed species kept
in an affected establishment, samples from these animals
should be collected for further laboratory examinations.
The lack of information on the performance of laboratory
tests (sensitivity, specificity) in these animal species along
with the lack of validation of the diagnostic methods in
them will increase the uncertainty on the reliability of the
sampling strategy.
See also 1st scenario in Section 4.1.1.1 and 2nd scenario
in Section 4.1.1.2 on sampling procedures.
5th scenario
Section 4.1.1.5. For





No specific guidelines on sampling procedures for
clinical or laboratory examination were found for the
5th scenario.
Several wild animals of listed
species for FMD have been
reported to be infected in the
literature and all seven serotypes
of FMDV have been detected.
Nonetheless, there is no evidence
to demonstrate their
epidemiological involvement to the
Surveillance of wildlife in the surroundings of an affected
establishment may include the visual inspection of these
animals from a distance and the inspection of any dead
animal found, hunted and trapped animals to identify
clinical signs compatible with FMD.
On the occurrence of clinical signs laboratory examination
should be followed.
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spread or maintenance of FMDV. It
is feasible that they could act as
spill over hosts and so potentially
could be a source of infection for
livestock.
African buffaloes (Syncerus caffer)
and some species of antelopes
that are not natural inhabitants of
the European Continent.
The available diagnostic methods
for FMD may not be validated for
these animals.
The lack of information on the performance of laboratory
tests (sensitivity, specificity) in these animal species along
with the lack of validation of the diagnostic methods in
them will increase the uncertainty on the reliability of the
sampling strategy.
See also 1st scenario in Section 4.1.1.1 for clinical
examination and sampling for laboratory examination in
case clinical signs are present.
See also 2nd scenario in Section 4.1.1.2 for laboratory









No specific guidelines on sampling procedures for a
clinical or laboratory examination were found for the
6th Scenario.
Based on kernels estimations (see
also Section 4.3.1) the median
probability of FMD transmission of
one affected establishment to
transmit FMD to another
establishment located up to 3 km
(within the current protection
zone) is 95.2%.
All the establishments located in the protection zone should
be visited and a minimum sample of animals should be
clinically examined with at least 95% confidence level to
detect or rule out the presence of animals with clinical
signs, as described in Section 4.1.1.1.
In case of sheep and goat, the sampling should be able to
detect or rule out the presence of FMD, with a confidence








No specific guidelines on sampling procedures for a
clinical or laboratory examination were found for the
8th scenario.
Based on kernels estimations (see
also Section 4.3.1) the median
probability of FMD transmission
from an affected establishment
beyond the borders of a protection
zone of 3 km is 4.8% while the
probability of escaping beyond the
borders of the surveillance zone is
0.3%.
In case the surveillance activities
in the protection zone do not
identify other affected
establishments, the probability of
FMD having escaped beyond the
For the surveillance zone, it is recommended that the
efforts will be allocated to enhance passive surveillance by
increasing awareness in all establishments, industry and
public. In addition, the awareness of the veterinarians at
the slaughterhouses should be high during the ante-
mortem animal inspection and post-mortem inspection of
the mouth and the feet in particular for sheep.
Any establishment where more generic signs of the disease
such as fever, lethargy, lost appetite, nasal/ophthalmic/oral
discharge, oedema of the limbs, lameness and even
changes in the individual animal behaviour, in the feed
intake and productivity, should be visited, the animals
should be clinically examined and samples should be
collected following the procedures described in
Sections 4.1.1.1 and 4.1.1.2.
Establishments in the surveillance zone epidemiologically
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limits of the protection zone into
the surveillance zone is very low.
linked to an affected establishment or to any other
establishment in the protection zone should be also visited;
the animals should be clinically examined, and samples
should be collected in case a suspicion is raised following
the procedures described in Sections 4.1.1.1 and 4.1.1.2.













No specific guidelines on sampling procedures for
clinical or laboratory examination were found for the
9th scenario in EU legislation.
This scenario describes three
different subscenarios: a) the need
to transfer animals of listed species
located in the protection zone to
slaughterhouse located within the
protection zone, b) the need to
transfer animals of listed species
located in the protection zone to
slaughterhouse located within the
surveillance zone; and c) the need
to transfer animals of listed species
located within the protection zone
to slaughterhouse located outside
the restricted zone. The highest
risk of spread due to movement of
undiagnosed animals is associated
with subscenario c.
All the animals in the establishment of origin should be
clinically examined before their movement. Following the
procedures described in Section 4.1.1.1.
In an establishment where the number of animals is large,
and therefore, the individual clinical examination of all the
animals is not feasible, a minimum sample of animals
(including all animals to be moved) should be clinically
examined with at least 95% confidence level to detect or
rule out the presence of animals with clinical signs, as
described in Section 4.1.1.1.
In case clinical signs compatible to FMD are identified, the
establishment is considered suspected and the procedures
for the laboratory confirmation that are described in
Section 4.1.1.1 should be followed and any movements
should be prohibited.
If animals of listed species for FMD of an establishment
located in the protection zone are to be dispatched to
slaughterhouses located outside the restricted zone
(subscenario c), then in addition to the clinical
examination, sampling for laboratory examination should
be performed following the procedures described in







protection zone to a
plant approved for
No specific guidelines on sampling procedures for
clinical or laboratory examination were found for the
12th scenario in EU legislation.
This scenario is very similar to the
scenario 9th of Section 4.1.2.1.
This scenario is very similar to the 9th scenario of
Section 4.1.2.1; therefore, the same procedures will be
followed for this scenario as well.
www.efsa.europa.eu/efsajournal 53 EFSA Journal 2021;19(6):6632
Control measures of Foot and Mouth Disease
Sampling
procedure
Laboratory guidelines based on Council























No specific guidelines on sampling procedures for
clinical or laboratory examination were found for the
13th scenario in EU legislation.
This scenario describes three
different subscenarios: the need to
transfer animals of listed species
located in the surveillance to
slaughterhouse located within the
surveillance zone (a), the need to
transfer animals of listed species
located in the surveillance zone to
slaughterhouse located outside the
surveillance zone (b); the need to
transfer animals of listed species
located outside the surveillance
zone to slaughterhouse located
within the surveillance zone (c).
Overall, it is true what assessed in
4.1.2.1. The highest risk of spread
is associated with the subscenario
(b) where animals move from a
higher risk zone to a lower risk
zone.
All the animals in the establishment of origin should be
clinically examined before their movement. Following the
procedures described in Section 4.1.1.1.
If dispatch of animals of listed species located in the
surveillance zone is to slaughterhouses located outside the
surveillance zone (subscenario b), then in addition to
clinical examination, sampling for laboratory examination
should be performed following the procedures described in
Section 4.1.1.2, in order to exclude infected but subclinical
animals.
In an establishment where the number of animals is large
and therefore the individual clinical examination of all the
animals is not feasible, a minimum sample of animals
(including all animals to be moved) should be clinically
examined with at least 95% confidence level to detect or
rule out the presence of animals with clinical signs, as
described in Section 4.1.1.1.
In case clinical signs compatible to FMD are identified, the
establishment is considered suspected and the procedures
for the laboratory confirmation that are described in
Section 4.1.1.1 should be followed and any movements
should be prohibited.
If dispatch of animals of listed species located in the
protection zone is to slaughterhouses located outside the
restricted zone (subscenario b), then sampling should be
performed following the procedures described in





Directive 2003/85 article 38: Member States shall
ensure that animals of susceptible species shall not
be removed from holdings within the surveillance
Animals in surveillance zone for
which a specific derogation has
been granted to be moved to
All the animals in the establishment of origin should be
clinically examined before their movement to pastures
following the procedures described in Section 4.1.1.1.
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zone. However, by way of derogation, this
prohibition shall not apply to movement of animals
for leading them without coming into contact with
animals of susceptible species of different holdings to
pasture situated within the surveillance zone not
earlier than 15 days after the last outbreak of foot
and mouth disease has been recorded in the
protection zone. In addition, movements of animals
to pastures shall be authorised by the competent
authority only after an examination by an official
veterinarian of all the animals of susceptible species
on the holding, including testing.
pastures should be subjected to
clinical surveillance, including
laboratory examinations.
Sampling procedures for laboratory
examination should ensure that
the animals do not pose a risk of
transmission with a confidence
level of 95%.
Animals of the holding that are
negative at the clinical examination
and are negative to laboratory
examinations according to
procedures described in
Section 4.1.1.2 do pose negligible
risk of transmission of FMD.
In case clinical signs compatible to FMD are identified, the
establishment is considered suspected, and the procedures
for the laboratory confirmation that are described in
Section 4.1.1.2 should be followed and any movements
should be prohibited.
The dispatch of animals of listed species for FMD to
pastures situated in the surveillance zone should be done
after sampling for laboratory examination, following the
procedures described in Section 4.1.1.1, in order to
exclude infected but subclinical animals with a confidence
level of 95%.
In an establishment where the number of animals is large,
and therefore, the individual clinical examination of all the
animals is not feasible, a minimum sample of animals
(including all animals to be moved) should be clinically
examined with at least 95% confidence level to detect or
rule out the presence of animals with clinical signs, as








located in or outside
the surveillance zone
No specific guidelines on sampling procedures for
clinical or laboratory examination were found for the
15th scenario in EU legislation.
Animals in surveillance zone for
which a specific derogation has
been granted to be moved to an
establishment of the same supply
chain located in or outside the
surveillance zone should be
subjected to clinical surveillance,
including laboratory examinations.
Sampling procedures for laboratory
examination should ensure that
the animals do not pose a risk of
transmission with a confidence
level of 95%.
Animals of the holding that are
negative at the clinical examination
and are negative at the laboratory
examinations according to
All the animals in the establishment of origin should be
clinically examined before their movement to an
establishment belonging to the same supply chain,
following the procedures described in Section 4.1.1.1.
In an establishment where the number of animals is large
and therefore the individual clinical examination of all the
animals is not feasible, a minimum sample of animals
(including all animals to be moved) should be clinically
examined with at least 95% confidence level to detect or
rule out the presence of animals with clinical signs, as
described in Section 4.1.1.1..
In case clinical signs compatible to FMD are identified, the
establishment is considered suspected and the procedures
for the laboratory confirmation that are described in
Section 4.1.1.1 should be followed and any movements
should be prohibited.
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procedures described in
Section 4.1.1.1 do pose negligible
risk of transmission of FMD.
The dispatch of animals of listed species for FMD to an
establishment belonging to the same supply chain should
be done after sampling for laboratory examination,
following the procedures described in Section 4.1.1.2, in
order to exclude infected but subclinical animals with a











set out in Annex XI
of the Delegated
Regulation
No specific guidelines on sampling procedures for
clinical or laboratory examination were found for the
18th scenario.
Animals in the restricted zone, for
which a specific derogation has
been granted to be moved within
the restricted zone, should be
subjected to clinical surveillance; if
they are not immediately
slaughtered, they should also be
sampled for laboratory
examinations.
Sampling procedures for laboratory
examination should ensure that
the animals do not pose a risk of
transmission with a confidence
level of 95%.
Animals of the holding that are
negative at the clinical examination
and are negative according to
laboratory procedures described in
Section 4.1.1.2 do pose negligible
risk of transmission of FMD.
The same sampling procedures, according to different
scenarios, should be implemented as those described in
Sections 4.1.2.1, 4.1.2.3, 4.1.2.4 and 4.1.2.5
ToR 1: For repopulation purposes
19th scenario
Section 4.1.3.1 For




No specific guidelines on sampling procedures for
laboratory examination were found for the 19th
scenario.
Clinical examination and sampling
should be used as standard
procedures to ensure that the
animals do not pose a risk of
transmission with a confidence
level of 95%.
Moving animals from non-affected
establishments that are negative at
Animals should be subjected to clinical examination.
In an establishment, where the number of animals is large,
and therefore, the individual clinical examination of all the
animals is not feasible, a minimum sample of animals
(including all animals to be moved) should be clinically
examined with at least 95% confidence level to detect or
rule out the presence of animals with clinical signs, as
described in Section 4.1.1.1.
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the clinical examination and found
negative to laboratory
examination, according to the
procedures described in
Section 4.1.1.1, minimise the risk
of FMDV transmission.
If animals are sourced from restricted areas, all the
animals in the establishment of origin should be sampled.
Sampling procedures for laboratory examination should
ensure that the animals do not pose a risk of transmission
with a confidence level of 95%. Laboratory examinations
should be in accordance to the procedures described in
Section 4.1.1.1.
In case clinical signs compatible to FMD, are identified the
establishment is considered suspected and the procedures
for the laboratory confirmation that are described in
Section 4.1.1.1 should be followed. The animals intended
for the repopulation even clinically healthy should not be
dispatched.
In case the animals originate from establishments located
in free areas, there is no need for laboratory examination if
there are no other reasons based on the authorities’ risk
assessment to recommend it (e.g. epidemiological link with
an affected establishment or with an affected or high-risk









No specific guidelines on sampling procedures for
laboratory examination were found for the 20th
scenario.
In case of unusual mortalities or
clinical signs compatible to FMD,
notified during the repopulation is
important to rule out the presence
of the disease.
In the event of animals with clinical signs compatible to
FMD, as they have been described in Section 4.1.1.1,
notified during the repopulation the establishment is
considered suspected. The repopulation should be stopped
and the procedures for the laboratory confirmation that are
described in Section 4.1.1.1 should be followed.
In addition, the establishments from where the suspected
animals coming from, should be considered as suspected.
The procedures that are described in Section 4.1.1.1






Pursuant Annex V of the directive 2003/85 :
‘1.3 Irrespective of the type of farming practised on
the holding, re-introduction must conform with the
following procedures:
1.3.1. animals must be introduced in all units and
Following restocking animals
should be thoroughly examined
clinically and by laboratory
examinations in order to rule out
the presence of the disease.
Animals must be subjected to clinical inspection every
three days for the first 14 days following the introduction,
and weekly from 15 to 28 days after re-introduction. The
last day of the monitoring period following the latest day of
animals’ introduction, all the animals should be subjected
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buildings of the holding involved;
1.3.2 in the case of a holding consisting of more
than one unit or building, re-introduction is not
necessary for every unit or building at the same
time; However no animals of species susceptible to
foot and mouth disease may leave the holding until
all the re-introduced animals in all units and buildings
have fulfilled all restocking procedures.
1.3.3 animals must be subjected to clinical inspection
every three days for the first 14 days following the
introduction;
1.3.4 during the period from 15 to 28 days after re-
introduction, animals are to be subjected to clinical
inspection once every week;
1.3.5 not earlier than 28 days after the last re-
introduction, all animals must be clinically examined
and samples for testing for the presence of antibody
against foot and mouth disease virus shall be taken
in accordance with the requirements of point 2.2 of
Annex III;
1.4 The restocking procedure shall be considered
completed when the measures provided for in point
1.3.5 have been completed with negative results.’
to thorough clinical examination as described in
Section 4.1.1.1 and should be sampled for laboratory





Assessment of the length
of the monitoring period of
FMD
Scenarios 1, 2, 3, 4, 6 and 7
Based on the results of the ELS as presented in Table 6 in
Section 4.2.1:
– the longest length of the period between infection and
suspicion of FMD is 26 days in cattle, 21 in pigs and 19
days in small ruminants;
– the average length was 13 days in cattle, 12 in pigs and
14 days in small ruminants
– the shortest length was 6 days in cattle, 3 in pigs and
9.5 days in small ruminants;
Scenario 5
Based on the results of the scientific publications as
Scenarios 1, 2 and 3
The length of the monitoring period of 21 days as defined in the Delegate
Regulation is considered effective, except for the first affected establishments in an
area where 26 days is recommended.
Scenario 4
As the disease has already been detected in the area, and high awareness is
expected, the length of the monitoring period is considered effective in this
scenario.
Scenario 5
Consequently and based on the results of the publications, sampling the animals at
least 28 (21 + 7) days after semen collection as it is foreseen in the Delegated
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presented in Table 7 and Table 8 in Section 4.2.1., the
latest date of seroconversion in non-vaccinated, naive
animals was identified as 15 days post infection by NSP
ELISA while for non-vaccinated, naive animals infected
trough contact with already infected animals was identified
as 28 days post contact by NSP ELISA.
In vaccinated animals, where there is already a level of
immunity, the detection of seroconversion after infection or
contact may be delayed.
Regulation is considered effective to detect antibodies with several laboratory
methods, given that the infection occurred at the latest at the day of semen
collection.







The defined minimum radiuses of 3 km and 10 km of the
protection and the surveillance zone, respectively, are
considered effective to restrain the spread of FMD beyond
their borders if it were to occur with a confidence level of
95% and 99%, respectively.
Based on the estimations of the kernels, as long as the radiuses of the zones are
increasing the probability of transmission outside the defined zones is decreasing as
well. Taken into consideration the local epidemiological situation, the density of the
establishments and the commercial activities different combinations of radiuses in
the protection and the surveillance zones may be selected to further decrease the




Based on the results of the ELS as presented in Table 6 in
Section 4.2.1 it follows that the average time between
introduction and suspicion is 13 days in cattle, 12 in pigs
and 14 days in small ruminants. The maximum period
between introduction and suspicion is 26 days in cattle, 21
in pigs and 19 days in small ruminants. Consequently, the
minimum period of 30 days indicated in the Delegated
Regulation for the restriction measures is considered
effective to detect affected establishments and to prevent
the movement of infected animals from the surveillance
zone.
None
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Abbreviations
ASF African swine fever
AHS African horse sickness
CSF Classical swine fever
CBPP Contagious bovine pleuropneumonia
CCPP Contagious caprine pleuropneumonia
CO Cut-off (of a diagnostic test)
dpi days post inoculation/infection
dpc days post contact
ELISA enzyme-linked immunosorbent assay
ELS extensive literature search
FMD Foot and mouth disease
FMDV Foot and mouth disease virus
HPAI Highly Pathogenic Avian Influenza
LSDV Lumpy skin disease virus
NCDV Newcastle disease virus
OIE World Organisation for Animal Health
PCR polymerase chain reaction
PZ protection zone
RP rinderpest virus
RT-PCR reverse transcription polymerase chain reaction
RVFV Rift Valley fever virus
SPGP Sheep pox and goat pox
SZ surveillance zone
ToR Terms of Reference
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Annex A – Definitions in EU legislation
Terms Definitions
Clinical examination The clinical examination comprises: i) an initial general evaluation of the animal health status of the establishment which comprises all the animals of
listed species kept in the establishment; and ii) an individual examination of the animals included in the sample referred to in point (a). The sampling of
animals for clinical examination is carried out in accordance with point A.1 of Annex I for terrestrial animals (Delegated Regulation article 3)
Confined
establishment
Means any permanent, geographically limited establishment, created on a voluntary basis and approved for the purpose of movements, where the
animals are: a) kept or bred for the purposes of exhibitions, education, the conservation of species or research; b) confined and separated from
the surrounding environment; and c) subject to animal health surveillance and biosecurity measures; (AHL: Regulation 2016/429 article 4(48))
Epidemiological unit Means a group of animals with the same likelihood of exposure to a disease agent; (AHL: Regulation 2016/429 article 4(39))
Establishment Means any premises, structure or, in the case of open-air farming, any environment or place, where animals or germinal products are kept, on a
temporary or permanent basis, except for: a) households where pet animals are kept; b) veterinary practices or clinics; (AHL: Regulation 2016/
429 article 4(27))
Health status Means the disease status as regards the listed diseases relevant for a particular listed species with respect to: a) an animal; b) animals within: i)
an epidemiological unit; ii) an establishment; iii) a zone; iv) a compartment; v) a Member State; vi) a third country or territory; (AHL: Regulation
2016/429 article 4(34))
Infected zone Means a zone in which restrictions on the movements of kept and wild animals or products and other disease control and biosecurity measures
may be applied with the view to preventing the spread of a category A disease in the event of official confirmation of the disease in wild animals.
(Delegated Regulation article 2(15))
Kept animals Means animals which are kept by humans, including, in the case of aquatic animals, aquaculture animals; (AHL: Regulation 2016/429 article 4(5))
Outbreak Means the officially confirmed occurrence of a listed disease or an emerging disease in one or more animals in an establishment or other place
where animals are kept or located; (AHL: Regulation 2016/429 article 4 (40)
Protection zone Means a zone around and including the location of an outbreak, where disease control measures are applied in order to prevent the spread of the
disease from that zone; (AHL: Regulation 2016/429 article 4(42))
Listed diseases Means diseases listed in accordance with Article 5(1); (AHL: Regulation 2016/429 article 4 (18))
List of the diseases (AHL: Regulation 2016/429, Annex II)
Listed species Means an animal species or group of animal species listed in accordance with Article 8(2), or, in the case of emerging diseases, an animal species
or group of animal species which meets the criteria for listed species laid down in Article 8(2); (AHL: Regulation 2016/429 article 4(20))
List of species and groups of species (Commission Implemented Regulation 2018/1882)
Monitoring periods It is appropriate to follow a single approach for the measures to apply in the event of a category A disease. However, the epidemiology of
diseases should be taken into account to establish the appropriate moment for the competent authority to apply control measures and to carry
out investigations if there is suspicion or confirmation of those diseases. Therefore ‘monitoring periods’ should be provided, as reference time
frames for each category A disease affecting terrestrial animals based on incubation periods and other relevant elements that may affect the
spread of the disease. (Delegated Regulation, whereas 10).
Restricted zone Means a zone in which restrictions on the movements of certain animals or products and other disease control measures are applied, with a view
to preventing the spread of a particular disease into areas where no restrictions are applied; a restricted zone may, when relevant, include
protection and surveillance zones; (AHL: Regulation 2016/429 article 4(41))
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Terms Definitions
Surveillance zone Means a zone which is established around the protection zone, and where disease control measures are applied in order to prevent the spread of
the disease from the protection zone; (AHL: Regulation 2016/429 article 4(43))
Wild animals Means animals which are not kept animals; (AHL: Regulation 2016/429 article 4(8))
Zone Means: (a) for terrestrial animals, an area of a Member State, third country or territory with a precise geographical delimitation, containing an
animal subpopulation with a distinct health status with respect to a specific disease or specific diseases subject to appropriate surveillance,
disease control and biosecurity measures; (AHL: Regulation 2016/429 article 4 (35))
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Annex B – Scenarios of ToR 1
ToRs Legislation Scenario Description of the Scenario Elements of the Scenario
ToR 1.1
ToR 1.2
6(2) of the Delegated
Regulation
1st scenario To assess the effectiveness of disease-specific
sampling procedures of animals of listed species in
a suspected establishment, based on clinical
examination (TOR 1.1) and laboratory examination
(TOR 1.2), in their ability to detect a category A
disease in kept animals if the disease is present in
that establishment, or to rule it out if not present
(Art. 6 (2)).
• event of suspicion of a category A disease
• in an establishment
• kept animals of listed species
• the competent authority shall immediately conduct an
investigation to confirm or rule out the presence of the
suspected listed disease
• official veterinarians perform clinical examinations and collect
samples for laboratory examinations
ToR 1.2 Art. 12(3), Art. 7 (4)
(Preventive killing) of the
Delegated Regulation,
and Art. 57 Reg.2016/429
2nd
scenario
To assess the effectiveness of disease-specific
sampling procedures, based on laboratory
examination (ToR 1.2), in their ability to detect the
disease in the event of preventive killing, and in
their ability to support with the epidemiological
investigation (disease detection, prevalence
estimation, virus identification, etc.) in kept animals
of listed species in an affected establishment,
before or when they are killed or found dead. The
purposes of the epidemiological enquiry are
described in Article 57 of Regulation (EU)2016/429.
• affected establishment officially confirmed
• kept animals of listed species found dead or before/when they
are killed
• competent authority collects samples for laboratory examination
for the purposes of:
a) supporting the epidemiological enquiry:
 to identify the likely origin of the disease
 to calculate the likely length of time that the disease is
present
 to identify establishments where the animals could
have contracted the disease and movements from the
affected establishment that could have led to the
spread of the disease
 to obtain information on the likely spread of the listed
disease in the surrounding environment, including the
presence and distribution of disease vectors
b) confirming/ruling out disease in the event of preventive
killing
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ToRs Legislation Scenario Description of the Scenario Elements of the Scenario
ToR 1.1
ToR 1.2
Article 13(3)c of the
Delegated Regulation
3rd scenario To assess the effectiveness of disease-specific
sampling procedures based on clinical (ToR 1.1)
and laboratory (ToR 1.2) examinations of the
animals of listed species belonging to the
categories described in article 13(2)) of an affected
establishment, in order to grant a specific
derogation from killing these animals, while
ensuring that they do not pose a risk for the
transmission of the disease.
• affected establishment officially confirmed
• kept animals of listed species of specific categories
• animal categories based on article 13(2):
a) animals kept in a confined establishment
b) animals kept for scientific purposes or purposes related to
conservation of protected or endangered species
c) animals officially registered in advance as rare breeds
d) animals with a duly justified high genetic, cultural or
educational value
• the competent authority may grant specific derogation from
killing all the animals of listed species belonging to any of the
above categories in an affected establishment, provided that
specific conditions are fulfilled
• the animals should be subjected to clinical surveillance,
including laboratory examinations
• sampling procedures should ensure that the animals do not




Article 14(1) of the
Delegated Regulation
Art. 57 Reg.2016/429
4th scenario To assess the effectiveness of disease-specific
sampling procedures based on clinical (ToR 1.1)
and laboratory (ToR 1.2) examinations of the
animals of non-listed species kept in an affected
establishment, in their ability to ensure the
detection of the virus if the virus is present in these
species.
• kept animals of non-listed species of epidemiological relevance
for the control of the disease
• animals of non-listed species are those animals that are not
listed in Commission Implementing Regulation (EU) 2018/1882
for each of the category A diseases
• animal species acting purely as mechanical carriers of the virus
will not be covered
• the competent authority is not obliged to carry out the
sampling of non-listed species, but they may establish it in
addition to other measures
• sampling procedures to ensure detection of the virus in these
species
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ToRs Legislation Scenario Description of the Scenario Elements of the Scenario
ToR 1.1
ToR 1.2
Article 14(1) of the
Delegated Regulation
Art. 57 Reg.2016/429
5th scenario To assess the effectiveness of disease-specific
sampling procedures based on clinical (ToR 1.1)
and laboratory (ToR 1.2) examinations of the wild
animals of listed species within the affected
establishment and in its surroundings. The purpose
of the sampling procedures is to ensure the
detection of the virus, if the virus is present in
these wild species
• affected establishment officially confirmed
• wild animals of listed species within the establishment and in
the surroundings of the establishment
• the competent authority may establish these sampling
procedures in addition to other measures
• sampling procedures in wild animals of listed species to ensure




Article 26(2) of the
Delegated Regulation
6th scenario To assess the effectiveness of disease-specific
sampling procedures based on clinical (ToR 1.1)
and laboratory (ToR 1.2) examinations of the
animals of listed species in establishments located
in the protection zone. The purpose of the
sampling procedures is to ensure the detection of
the virus, if the virus is present in these animals.
• protection zone with radius up to 3 km
• non-affected establishments with kept animals of listed species
• all the non-affected establishments within the protection zone
• official veterinarians must visit at least once all the
establishments
• among others, they must perform a clinical examination of kept
animals of listed species and if necessary, collection of samples
for laboratory examination
• sampling procedures to confirm or rule out the presence of a
category A disease
ToR 1.3 Article 26(5) of the
Delegated Regulation
point A.3 of Annex I
7th scenario To assess the effectiveness of disease-specific
sampling procedures, based on clinical (ToR 1.1)
and laboratory (ToR 1.2) examinations of the
animals of listed species, for the sampling of
establishments located in a protection zone when
the radius is larger than 3 km. The purpose of the
sampling procedure is to ensure disease detection
of the virus if the virus is present in establishments
within the protection zone
• protection zone with radius larger than 3 km
• non-affected establishments of kept animals of listed species
• sample of the non-affected establishments in the protection
zone
• in a protection zone with a radius equal to 3 km, official
veterinarians must carry inspections in all establishments within
the 3 km
• In case of a radius larger than 3 km, official veterinarians may
not visit all establishments, but a sample of those. EFSA is
requested to assess how many of these establishments should
be inspected, in order to ensure the detection of the virus, if
the virus is present in animals in these establishments
• among others perform clinical examination of kept animals of
listed species and if necessary, collection of samples for
laboratory examination
• sampling procedure to ensure the detection of the disease if
the disease is present in any of these establishments
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ToRs Legislation Scenario Description of the Scenario Elements of the Scenario
ToR 1.3 Article 41 of the
Delegated Regulation
8th scenario To assess the effectiveness of disease-specific
sampling procedures, based on clinical (ToR 1.1)
and laboratory (ToR 1.2) examinations of the
animals of listed species, for the sampling of the
establishments located within the surveillance zone.
The purpose of the sampling procedure is to
ensure disease detection if the virus is present in
establishments within the surveillance zone
• surveillance zone
• establishments of kept animals of listed species
• sample of the establishments in the surveillance zone
• official veterinarians carry out visits to a sample of the
establishments
• among others perform clinical examination of kept animals of
listed species and if necessary, collection of samples for
laboratory examination
• sampling procedure to ensure the detection of the disease if
the disease is present in any of the establishments
Derogations to allow animal movements
ToR 1.4 Article 28(5) of the
Delegated Regulation
Article 29 of the
Delegated Regulation
9th scenario To assess the effectiveness of disease-specific
sampling procedures based on clinical and/or
laboratory examinations of the animals of an
establishment in a protection zone, in order to
grant a derogation from prohibitions in the
movement of animals, and allow for the animals to
be moved to a slaughterhouse located within the
protection zone or in the surveillance zone or
outside the restricted zone (Art29)
• protection zone
• kept animals of listed species
• grant derogation for movement from a non-affected
establishment in the protection zone
• to be moved to a slaughterhouse located within the protection
zone or in the surveillance zone or outside the restricted zone
• clinical examinations and laboratory examination of animals
kept in the establishment, including those animals to be moved
ToR 1.4 Article 28(5) and Article




To assess the effectiveness of disease-specific
sampling procedures based on clinical and/or
laboratory examinations, to grant a derogation
from prohibitions in the movement of day-old-
chicks located in the protection zone and hatched
from eggs originating in the restricted zone or
outside the restricted zone. The sampling
procedures should ensure that the movement of
these day-old-chicks to an establishment located in
the same Member State but if possible, outside the
restricted zone
• protection zone
• grant derogation for movement from a non-affected
establishment in the protection zone
• day-old-chicks from non-affected establishment located in the
protection zone, hatched from eggs originating in or outside
the restricted zone
• to be moved to an establishment located in the same Member
State but if possible, outside the restricted zone
• clinical examinations and laboratory examination of animals
kept in the establishment, including those animals to be moved
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ToRs Legislation Scenario Description of the Scenario Elements of the Scenario
ToR 1.4 Article 28(5) and Article




To assess the effectiveness of disease-specific
sampling procedures based on clinical and/or
laboratory examinations, to grant a derogation
from prohibitions in the movement of ready-to-lay
poultry located in the protection zone to
establishments located in the same MS and if
possible within the restricted zone.
• protection zone
• ready-to-lay poultry
• grant derogation for movement from a non-affected
establishment in the protection zone
• to be moved to an establishment located in the same Member
State and if possible, within the restricted zone
• clinical examinations and laboratory examination of animals
kept in the establishment, including those animals to be moved
ToR 1.4 Article 28(5) and Article




To assess the effectiveness of disease-specific
sampling procedures based on clinical and/or
laboratory examinations of the animals of an
establishment in a protection zone, in order to
grant derogation from prohibitions in the
movement of these animals to a plant approved for
processing or disposal of animal by-products in
which the kept animals are immediately killed
(Art37)
• protection zone
• kept animals of listed species
• grant derogation for movement from a non-affected
establishment in the protection zone
• to be moved to a plant approved for processing or disposal of
animal by-products in which the kept animals are immediately
killed
• clinical examinations and laboratory examinations of animals
kept in the establishment, including those animals to be moved
ToR 1.4 Article 43(5) and Article




To assess the effectiveness of disease-specific
sampling procedures based on clinical and/or
laboratory examinations of the animals of listed
species in order to grant derogation from
prohibitions and allow for these animals to be
moved: a) from an establishment in a surveillance
zone to a slaughterhouse located within or outside
the restricted zone, b)from an establishment
outside the surveillance zone to a slaughterhouse
situated in the surveillance zone
• surveillance zone
• kept animals of listed species
• grant derogation for movement from an establishment in the
surveillance zone to be moved to a slaughterhouse within the
restricted zone or outside the restricted zone
• grant derogation for movement from an establishment outside
the surveillance zone to a slaughterhouse situated in the
surveillance zone
• clinical examinations and laboratory examination of animals
kept in the establishment, including those animals to be moved
ToR 1.4 Article 43(5) and Article




To assess the effectiveness of disease-specific
sampling procedures based on clinical and/or
laboratory examinations of kept ungulates of listed
species in order to grant a derogation and allow for
the animals to be moved from an establishment in
the surveillance zone to pastures situated within
the surveillance zone
• surveillance zone
• kept ungulates of listed species
• grant derogation for movement from an establishment in the
surveillance zone
• to be moved to pastures situated within the surveillance zone
• clinical examinations and laboratory examination of animals
kept in the establishment, including those animals to be moved
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ToRs Legislation Scenario Description of the Scenario Elements of the Scenario
ToR 1.4 Article 43(5) and Article




To assess the effectiveness of disease-specific
sampling procedures based on clinical and/or
laboratory examinations of kept ungulates of listed
species in order to grant derogation and allow to
be moved from an establishment in the surveillance
zone to an establishment belonging to the same
supply chain, located in or outside the surveillance
zone, in order to complete the production cycle
before slaughter
• surveillance zone
• kept animals of listed species
• grant derogation for movement from the surveillance zone
• to be moved to an establishment belonging to the same supply
chain, located in or outside the surveillance zone, to complete
the production cycle before slaughter
• clinical examinations and laboratory examination of animals
kept in the establishment, including those animals to be moved
ToR 1.4 Article 43(5) and Article




To assess the effectiveness of disease-specific
sampling procedures based on clinical and/or
laboratory examinations to grant derogation of
movements of day-old-chicks hatched from
establishment located in the surveillance zone, from
eggs originating within the surveillance zone and
eggs originating outside the restricted zone, to an
establishment located in the same Member State
where they were hatched
• surveillance zone
• kept birds of listed species
• grant derogation for movement of day-old-chicks hatched from
establishment located in the surveillance zone, from eggs
originating from establishment within the surveillance zone or
eggs originating from outside the restricted zone
• to be moved to an establishment located in the same Member
State
• clinical examinations and laboratory examination of animals
kept in the establishment, including those animals to be moved
ToR 1.4 Article 43(5) and Article




To assess the effectiveness of disease-specific
sampling procedures based on clinical and/or
laboratory examinations, to grant a derogation
from prohibitions in the movement of ready-to-lay
poultry located in the surveillance zone to
establishments located in the same MS.
• surveillance zone
• ready-to-lay poultry
• to be moved to an establishment located in the same Member
State
• clinical examinations and laboratory examination of animals
kept in the establishment, including those animals to be moved




To assess the effectiveness of disease-specific
sampling procedures based on clinical and/or
laboratory examinations of the animals of an
establishment located in the restricted zone of an
outbreak in order to allow their move within the
restricted zone, when restriction measures are
maintained beyond the period set out in Annex XI
• restricted zone when restriction measures are maintained
beyond the period set out in Annex XI
• kept animals of listed species
• grant derogation for movement from an establishment within
the restricted zone
• clinical examinations and laboratory examination of animals
kept in the establishment, including those animals to be moved
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ToRs Legislation Scenario Description of the Scenario Elements of the Scenario
Repopulation




To assess the effectiveness of disease-specific
sampling procedures based on laboratory
examinations of the animals that are kept for the
repopulation prior to their introduction to rule out
the presence of the disease.
• repopulation of a previous affected establishment
• kept animals of listed species
• Animals intended to repopulation shall be sampled prior to their
introduction into the establishment of destination
• samples shall be collected from a representative number of
animals to be introduced of each consignment from each
establishment or from a representative number of animals of
each consignment (if animals are all to be introduced at
different times or from different establishments of origin)
• laboratory examinations
• sampling procedures to rule out the presence of the disease




To assess the effectiveness of disease-specific
sampling procedures based on laboratory
examinations of the animals that have been
repopulated, in the event of unusual mortalities or
clinical signs being notified during the repopulation;
to rule out the presence of the disease.
• repopulated establishment
• unusual mortalities or clinical signs during the repopulation
• the official veterinarians shall without delay collect samples for
laboratory examination
• sampling procedures to rule out the presence of the disease




To assess the effectiveness of disease-specific
sampling procedures based on laboratory
examinations of the animals that have been
repopulated, on the last day of the monitoring
period calculated forward from the date on which
the animals were placed in the repopulated
establishment. In case the repopulation takes place
in several days, the monitoring period will be
calculated forward from the last day in which the
last animal is introduced in the establishment.
• repopulated establishment
• kept animals of listed species
• Animals that have been used for repopulation
• Laboratory examinations
• Sampling procedures to rule out the presence of the disease
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Annex C – Existing sampling procedures for FMD
Sampling scenarios for FMD – Based on Council Directive 2003/85/EC if not stated otherwise
Scenario Description of the Scenario Clinical guidelines Laboratory guidelines
1st To assess the effectiveness of disease-
specific sampling procedures of animals of
listed species in a suspected establishment,
based on clinical examination (TOR 1.1) and
laboratory examination (TOR 1.2), in their
ability to detect a category A disease in
kept animals if the disease is present in that
establishment, or to rule it out if not
present (Art. 6 (2)).
Annex III
1. Clinical examination
1.1. Holdings must undergo clinical examinations
of all animals of susceptible species for signs or
symptoms of foot and mouth disease.
1.2. Special emphasis must be laid on animals
which may have been exposed to foot and mouth
disease virus with a high probability, notably
transport from holdings at risk or close contact to
persons or equipment that had close contact to
holdings at risk.
1.3. The clinical examination must take into
account the transmission of foot and mouth
disease, including the incubation period referred
to in Article 2(h) and the way in which animals of
susceptible species are kept.
1.4. Relevant records kept on the holding must be
examined in detail with particular regard to data
required for animal health purposes by
Community legislation and, where available, on
morbidity, mortality
and abortion, clinical observations, changes in
productivity and feed intake, purchase or sale of
animals, visits of persons likely to be
contaminated and other anamnestically important
information.
Annex III 2.1.1.
Serological sampling shall be carried out according to the
recommendations of the epidemiological team established
within the expert group referred to in Article 78, and
Annex III 2.2.
Sampling on holdings: In holdings where the presence of
foot and mouth disease is suspected but in the absence of
clinical signs, sheep and goats, and on recommendation of
the epidemiological team other susceptible species, should
be examined pursuant to a sampling protocol suitable to
detect 5% prevalence with at least 95% level of
confidence.
OIE Terrestrial Manual 2018 (p.436-437)
For laboratory diagnosis, the tissue of choice is epithelium
or vesicular fluid. Ideally, at least 1 g of epithelial tissue
should be collected from an unruptured or recently
ruptured vesicle, usually from the tongue, buccal mucosa
or feet. Where epithelial tissue is not available from
ruminant animals, for example in advanced or convalescent
cases, or where infection is suspected in the absence of
clinical signs, samples of OP fluid can be collected by
means of a probang (sputum) cup (or in pigs by swabbing
the throat) for submission to a laboratory for virus isolation
or reverse-transcription polymerase chain reaction (RT-
PCR). Viraemia may also be detected by examining serum
samples by means of RT-PCR or virus isolation.
• A range of sample types, including epithelium, OP
samples, milk and serum, may be examined by virus
isolation or RT-PCR. By contrast, ELISA CF and the lateral
flow device are suited to the examination of epithelial
suspensions, vesicular fluids or cell culture supernatants,
but are insufficiently sensitive for the direct examination
of OP samples or serum.
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Scenario Description of the Scenario Clinical guidelines Laboratory guidelines
2nd To assess the effectiveness of disease-
specific sampling procedures, based on
laboratory examination (ToR 1.2), in their
ability to detect the disease in the event of
preventive killing and in their ability to
support with the epidemiological
investigation (disease detection, prevalence
estimation, virus identification, etc.) in kept
animals of listed species in an affected
establishment, before or when they are
killed or found dead. The purposes of the
epidemiological enquiry are described in
Article 57 of Regulation (EU)2016/429.
No specific guidelines described in legislation. No specific guidelines are described in this piece of
legislation for other subscenarios
3rd To assess the effectiveness of disease-
specific sampling procedures based on
clinical (ToR 1.1) and laboratory (ToR 1.2)
examinations of the animals of listed
species belonging to the categories
described in article 13(2)) of an affected
establishment, in order to grant a specific
derogation from killing these animals, while
ensuring that they do not pose a risk for
the transmission of the disease.
No specific guidelines described in legislation No specific sampling procedures are described in this piece
of legislation describing the sampling procedures in animals
of listed species, to grant a derogation from killing these
animals
4th To assess the effectiveness of disease-
specific sampling procedures, based on
clinical (ToR 1.1) and laboratory (ToR 1.2)
examinations of the animals of non-listed
species kept in an affected establishment,
in their ability to ensure the detection of the
virus if the virus is present in these species.
No specific guidelines described in legislation.
Article 2 (a): ‘animal of a susceptible species’
means any domestic or wild animal of the
suborders Ruminantia, Suina and Tylopoda of the
order Artiodactyla;
For specific measures, notably in application of
Article 1(2), Article 15 and Article 85(2), other
animals, such as for example of the order
Rodentia or Proboscidae, may be considered
susceptible to foot and mouth disease in
accordance with scientific evidence.
There is no concept of listed species in Directive
2003/85 but instead the term susceptible species
is used.
No specific guidelines described in legislation
No specific guidelines described in legislation
No specific guidelines described in legislation
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Scenario Description of the Scenario Clinical guidelines Laboratory guidelines
5th To assess the effectiveness of disease-
specific sampling procedures, based on
clinical (ToR 1.1) and laboratory (ToR 1.2)
examinations of the wild animals of listed
species within the affected establishment
and in its surroundings. The purpose of the
sampling procedures is to ensure the
detection of the virus, if the virus is present
in these wild species
No specific guidelines described in legislation No specific guidelines described in legislation
6th To assess the effectiveness of disease-
specific sampling procedures based on
clinical (ToR 1.1) and laboratory (ToR 1.2)
examinations of the animals of listed
species in establishments located in the
protection zone. The purpose of the
sampling procedures is to ensure the
detection of the virus, if the virus is present
in these animals.
Annex III,
All holdings with animals of susceptible species
shall periodically undergo a veterinary inspection,
carried out in such a way as to avoid the spread
of foot and mouth disease virus possibly present
on the holdings, which shall include in particular
the relevant documentation, notably the records
referred to in subparagraph (a) and the measures
applied to prevent the introduction or escape of
foot and mouth disease virus and which may
include clinical inspection as described in point 1
of Annex III or taking of samples from animals of
susceptible species in accordance to the
recommendations of the epidemiological team
established within the expert group referred to in
Article 78.
The clinical inspection should be done as
described for scenario 1
The sampling in protection zone described in Annex III
is referring to the freedom of the disease in the area.
No specific sampling procedures for the early detection of
the virus are described in this piece of legislation.
8th To assess the effectiveness of disease-
specific sampling procedures, based on
clinical (ToR 1.1) and laboratory (ToR 1.2)
examinations of the animals of listed
species, for the sampling of the
establishments located within the
surveillance zone. The purpose of the
sampling procedure is to ensure disease
detection if the virus is present in
establishments within the surveillance zone
ANNEX III
2.4. Sampling in surveillance zones
In order to seek the repeal in accordance with
Article 44 of the measures provided for in Articles
37 to 43, holdings within the perimeters of the
surveillance zone where the presence of foot and
mouth disease in the absence of clinical signs
must be suspected, notably where sheep and
goats are kept, shall be examined.
The sampling in surveillance zone described in Annex III
is referring to the freedom of the disease in the area.
No specific sampling procedures for the early detection of
the virus are described in this piece of legislation.
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Scenario Description of the Scenario Clinical guidelines Laboratory guidelines
Derogations to allow animal movements
9th To assess the effectiveness of disease-
specific sampling procedures based on
clinical and/or laboratory examinations of
the animals of an establishment in a
protection zone, in order to grant a
derogation from prohibitions in the
movement of animals, and allow for the
animals to be moved to a slaughterhouse
located within the protection zone or in the
surveillance zone or outside the restricted
zone (Art29)
2. By way of derogation from paragraph 1(c),
animals of susceptible species may be transported
under official supervision for the purpose of
emergency slaughter directly to a slaughterhouse
situated inside the same protection zone, or if that
zone has no slaughterhouse to a slaughterhouse
outside the zone designated by the competent
authority in means of transport cleansed and
disinfected under official control after each
transport operation. The movement referred to in
the first subparagraph shall only be authorised if
the competent authority is satisfied on the basis
of a clinical examination in accordance with point
1 of Annex III by the official veterinarian of all the
animals of susceptible species present on the
holding and after evaluation of epidemiological
circumstances that there is no reason to suspect
the presence of infected or contaminated animals
on the holding.
Annex III
2.3. Sampling in protection zones
In order to seek the repeal in accordance with Article 36 of
the measures provided for in Articles 21 to 35, all holdings
within the perimeters of the protection zone where sheep
and goats have not been in direct and close contact with
bovine animals during a period of at least 21 days prior to
taking the samples shall be examined pursuant to a
sampling protocol suitable to detect 5% prevalence of
disease with at least 95% level of confidence.
However, the competent authorities may decide where
epidemiological circumstances allow and in particular in
application of the measures provided for in Article 36(1)
(b), that samples are taken not earlier than 14 days after
the elimination of susceptible animals on the infected
holding(s) and the carrying out of preliminary cleansing
and disinfection, under the condition that the sampling is
carried out in accordance with point 2.3 using statistical
parameters suitable to detect 2% prevalence of disease
within the herd with at least 95% level of confidence.
12th To assess the effectiveness of disease-
specific sampling procedures based on
clinical and/or laboratory examinations of
the animals of an establishment in a
protection zone, in order to grant
derogation from prohibitions in the
movement of these animals to a plant
approved for processing or disposal of
animal by-products in which the kept
animals are immediately killed (Art37)
No specific guidelines described in legislation No specific guidelines described in legislation
13th To assess the effectiveness of disease-
specific sampling procedures based on
clinical and/or laboratory examinations of
the animals of listed species in order to
grant derogation from prohibitions and
allow for these animals to be moved:
Article 37
2. By way of derogation from the prohibition
provided for in Article 22(1)(c) and where there is
no or insufficient slaughter capacity available
within the surveillance zone, the competent
authorities may authorise the removal from
No specific guidelines described in legislation
Movements of animals provided for in paragraph 2(a)
shall be authorised by the competent authority only after
an examination by an official veterinarian of all the animals
of susceptible species on the holding, including testing of
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Scenario Description of the Scenario Clinical guidelines Laboratory guidelines
a) from an establishment in a surveillance
zone to a slaughterhouse located within
or outside the restricted zone,
b) from an establishment outside the
surveillance zone to a slaughterhouse
situated in the surveillance zone
holdings situated in the surveillance zone of
animals of susceptible species for transporting
them directly and under official supervision for
slaughter to a slaughterhouse located outside the
surveillance zone, subject to the following
conditions:
(a) the records referred to in Article 22(1) have
been subjected to official control, and the
epidemiological situation of the holding does not
indicate any suspicion of infection or
contamination with the foot and mouth disease
virus,
(b) all the animals of susceptible species on the
holding have been subjected with negative result
to an inspection by the official veterinarian,
(c) a representative number of animals, taking
into account the statistical parameters in point 2.2
of Annex III, has been subjected to thorough
clinical examination to rule out the presence or
suspicion of clinically infected animals,
(d) the slaughterhouse is designated by the
competent authority
and located as near to the surveillance zone as
possible and
(e) the meat produced from such animals shall be
subjected to the treatment specified in Article 39.
No specific guidelines
samples taken in accordance with point 2.2 of Annex III,
has ruled out the presence of animals suspected of being
infected or animals suspected of being contaminated (2.2
of Annex III- In holdings where the presence of foot and
mouth disease is suspected but in the absence of clinical
signs, sheep and goats, and on recommendation of the
epidemiological team other susceptible species, should be
examined pursuant to a sampling protocol suitable to
detect 5% prevalence with at least 95% level of
confidence.).
14th To assess the effectiveness of disease-
specific sampling procedures based on
clinical and/or laboratory examinations of
kept ungulates of listed species in order to
grant a derogation and allow for the
animals to be moved from an establishment
in the surveillance zone to pastures situated
within the surveillance zone
No specific guidelines
Art 38 of the Directive 2003/85: ‘1. Member
States shall ensure that animals of susceptible
species shall not be removed from holdings within
the surveillance zone. 2. By way of derogation,
the prohibition provided in paragraph 1 shall not
apply to movement of animals for one of the
following purposes: (a) for leading them without
coming into contact with animals of susceptible
species of different holdings, to pasture situated
within the surveillance zone not earlier than
No specific guidelines described in legislation
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Scenario Description of the Scenario Clinical guidelines Laboratory guidelines
15 days after the last outbreak of FMD has been
recorded in the protection zone./. . ./ 3.
Movements of animals provided for in paragraph 2
(a) shall be authorised by the competent authority
only after an examination by an official
veterinarian of all the animals of susceptible
species on the holding, including testing samples
taken in accordance with /. . .’
15th To assess the effectiveness of disease-
specific sampling procedures based on
clinical and/or laboratory examinations of
kept ungulates of listed species in order to
grant derogation and allow to be moved
from an establishment in the surveillance
zone to an establishment belonging to the
same supply chain, located in or outside the
surveillance zone, in order to complete the
production cycle before slaughter
No specific guidelines described in legislation No specific guidelines described in legislation
18th To assess the effectiveness of disease-
specific sampling procedures based on
clinical and/or laboratory examinations of
the animals of an establishment located in
the restricted zone of an outbreak in order
to allow their move within the restricted
zone, when restriction measures are
maintained beyond the period set out in
Annex XI
No specific guidelines described in legislation No specific guidelines described in legislation
Repopulation
19th To assess the effectiveness of disease-
specific sampling procedures based on
laboratory examinations of the animals that
are kept for the repopulation prior to their
introduction to rule out the presence of the
disease
ANNEX V
1.1. Restocking should not commence until 21
days after completion of the final disinfection of
the holding.
1.2. Animals for restocking can only be introduced
under the following conditions:
1.2.1. the animals shall not come from areas
subject to animal health restrictions in relation to
foot and mouth disease;
ANNEX V
1.3. Irrespective of the type of farming practised on the
holding, re-introduction must conform with the following
procedures:
1.3.1. animals must be introduced in all units and buildings
of the holding involved;
1.3.2. in the case of a holding consisting of more than one
unit or building, re-introduction is not necessary for every
unit or building at the same time;
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Scenario Description of the Scenario Clinical guidelines Laboratory guidelines
1.2.2. the competent authorities must be satisfied
that any possible residual foot and mouth disease
virus can be detected in the animals intended for
restocking either on the base of clinical signs, in
the case of
bovine or porcine animals, or though laboratory
investigations in the case of other species
susceptible to foot and mouth disease, carried out
at the end of the observation period specified in
paragraph 1.3;
1.2.3. in order to ensure an adequate immune
response referred to in paragraph 1.2.2 in the
animals intend for restocking, the animals must:
1.2.3.1. either originate in and come from a
holding situated in an area of at least 10 km
radius centred on that holding where there was
no outbreak of foot and mouth disease for at least
30 days, or
1.2.3.2. the animals have been tested with
negative results in an assay as described in Annex
XIII for the detection of antibodies against the
foot and mouth disease virus carried out on
samples taken prior to introduction onto the
holding.
1.3.3. animals must be subjected to clinical
inspection every three days for the first 14 days
following the introduction;
1.3.4. during the period from 15 to 28 days after
re-introduction, animals are to be subjected to
clinical inspection once every week;
1.3.5. not earlier than 28 days after the last re-
introduction, all animals must be clinically
examined and samples for testing for the
presence of antibody against foot and mouth
disease virus shall be taken in
accordance with the requirements of point 2.2 of
Annex III;
However no animals of species susceptible to foot and
mouth disease may leave the holding until all the re-
introduced animals in all units and buildings have fulfilled
all restocking procedures.
1.3.3. animals must be subjected to clinical inspection
every three days for the first 14 days following the
introduction;
1.3.4. during the period from 15 to 28 days after re-
introduction, animals are to be subjected to clinical
inspection once every week;
1.3.5. not earlier than 28 days after the last re-
introduction, all animals must be clinically examined and
samples for testing for the presence of antibody against
foot and mouth disease virus shall be taken in
accordance with the requirements of point 2.2 of
Annex III;
1.4. The restocking procedure shall be considered
completed when the measures provided for in point 1.3.5
have been completed with negative results.
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Scenario Description of the Scenario Clinical guidelines Laboratory guidelines
1.4. The restocking procedure shall be considered
completed when the measures provided for in point
1.3.5 have been completed with negative results.
20th To assess the effectiveness of disease-
specific sampling procedures based on
laboratory examinations of the animals that
have been repopulated, in the event of
unusual mortalities or clinical signs being
notified during the repopulation; to rule out
the presence of the disease
No specific legislation for this scenario. No specific legislation for sampling in this scenario.
21st To assess the effectiveness of disease-
specific sampling procedures based on
laboratory examinations of the animals that
have been repopulated, on the last day of
the monitoring period calculated forward
from the date on which the animals were
placed in the repopulated establishment. In
case the repopulation takes place in several
days, the monitoring period will be
calculated forward from the last day in
which the last animal is introduced in the
establishment
No specific legislation for this scenario. No specific legislation for this scenario.
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Annex D – Scenarios of ToR 2
ToRs Legislation Scenario Description of the Scenario Elements of the Scenarios
ToR 2 Article 8 of the Delegated
Regulation
rticle 57 of 2016/429
Regulation
Annex II of the Delegated
Regulation
1st scenario To assess the effectiveness of the length of the
Monitoring Period, as the time period calculated
backwards from the date of the notification of the
suspicion of a category A disease in an
establishment with kept animals of listed species,
for the purposes of the epidemiological enquiry in
the event of a suspicion.
• event of suspicion of a category A disease
• in an establishment with kept animals of listed species
• time period calculated backwards from the date of the of the
notification of the suspicion
• time period before the suspicion, during which the pathogenic
agent may have been introduced in the establishment and
may have spread outside the establishment
• the aim of the epidemiological enquire is:
a) identify the likely origin of the listed disease in question and
the means of its spread
b) calculate the likely length of time that the listed disease has
been present
c) identify establishments and epidemiological units therein, food
and feed businesses or animal by–products establishments, or
other locations, where animals of listed species for the
suspected listed disease may have become infected, infested
or contaminated
d) obtain information on the movements of kept animals,
persons, products, vehicles, any material or other means by
which the disease agent could have been spread during the
relevant period preceding the notification of the suspicion or
confirmation of the listed disease
e) obtain information on the likely spread of the listed disease in
the surrounding environment, including the presence and
distribution of disease vectors
ToR 2 Article 17(2) and Article 57
of 2016/429 Regulation
Annex II of the Delegated
Regulation
2nd scenario To assess the effectiveness of the length of the
Monitoring Period, as the time period calculated
backwards from the date of notification of the
suspicion of a category A disease in an
establishment with kept animals of listed species,
for the purposes of the epidemiological enquiry in
the event of confirmation of the disease.
• event of confirmation of a category A disease
• in an establishment with kept animals of listed species
• time period calculated backwards from the date of the
notification of the suspicion
• time period before the suspicion, during which the pathogenic
agent was introduced in the establishment and during which it
could have spread outside the establishment.
• The aim of the epidemiological enquire is the same as above.
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ToRs Legislation Scenario Description of the Scenario Elements of the Scenarios
ToR 2 Article 13(b) of the
Delegated Regulation
Annex II of the Delegated
Regulation
3rd scenario To assess the effectiveness of the length of the
Monitoring Period, as the time period calculated
backwards from the date of confirmation of a
category A disease in an establishment with kept
animals of listed species, during which the
epidemiological units in which the disease has not
been confirmed were kept completely separated
and handled by different personnel, in order to
provide derogations from killing.
• event of confirmation of a category A disease
• in an affected establishment with kept animals of listed
species
• non-affected epidemiological units kept separated
• to provide derogation from killing for animals in non-affected
separated epidemiological units
• to exclude any possible contact between the affected
establishment and the separated epidemiological units as per
the epidemiological enquiry
• time period calculated backwards from the date of the
confirmation
• time period before the confirmation, during which the
pathogenic agent may have been introduced in the separated
non-affected epidemiological units of the affected
establishment.
ToR 2 Article 27(3)c of the
Delegated Regulation
Annex II of the Delegated
Regulation
4th scenario To assess the effectiveness of the length of the
Monitoring Period, as the time period calculated
backwards from the date of notification of the
suspicion of the latest outbreak of a category A
disease in the protection zone. Products or other
materials likely to spread the disease, must had
been obtained or produced, before this time period




• Products or other materials likely to spread the disease,
obtained or produced, before the start of the monitoring
period of the affected establishment that originated the
protection zone
• time period calculated backwards from the date of suspicion
of the latest outbreak in the protection zone
• time period before the notification of the suspicion, during
which the products and materials produced in the non-
affected establishments of a protection zone may have been
contaminated by the pathogenic agent of the disease.
Control measures of Foot and Mouth Disease
www.efsa.europa.eu/efsajournal 82 EFSA Journal 2021;19(6):6632
ToRs Legislation Scenario Description of the Scenario Elements of the Scenarios
ToR 2 Article 32(c) of the
Delegated Regulation
Article 48(c) of the
Delegated Regulation
Annex II of the Delegated
Regulation
5th scenario To assess the effectiveness of the length of the
Monitoring Period, as the time period calculated
forwards from the date of semen collection from
animals of listed species kept in approved germinal
product establishments in the protection or in the
surveillance zone, to prove that the donor animal
has tested favourable on a sample taken not earlier
than 7 days after the monitoring period.
• protection or surveillance zone
• non-affected approved germinal establishments
• semen from kept animals (donor) of listed species
• semen collected after the estimated date of the earliest
infection of the earliest affected establishment that originated
the protection zone/surveillance zone (if belonging to more
than one protection or surveillance zones)
• to take samples from the donor for laboratory analysis at least
7 days after the end of the monitoring period
• to authorise movements of semen from approved germinal
product establishments located in the protection or
surveillance zones in case of favourable laboratory results
• time period calculated forwards from the date of semen
collection
• time period after the semen collection, during which the
animal donor if infected could be detected by the relevant
diagnostic test.
ToR 2 Article 57(1)b of the
Delegated Regulation
Annex II of the Delegated
Regulation
6th scenario To assess the effectiveness of the length of the
Monitoring Period, as the appropriate time period
calculated forwards from the date after the final
cleaning and disinfection and when relevant control
of insects and rodents was carried out in an
affected establishment, after which the
repopulation of the establishment may be allowed
by the competent authority.
• repopulation of a previous affected establishment
• kept animals of listed species
• to allow the repopulation of an affected establishment
• time period calculated forwards from the date of the final
cleaning and disinfection of the establishment
• time period to ensure that the repopulation exercise is not put
at risk due to the disease being unknowingly present in an
establishment in the surrounding area.
ToR 2 Article 59(4)b of the
Delegated Regulation
Annex II of the Delegated
Regulation
7th scenario To assess the effectiveness of the length of the
Monitoring Period, as the appropriate time period
calculated forwards the date when the first animal
was introduced, during which all the animals of
listed species intended for repopulation should be
introduced.
• repopulation of a previous affected establishment
• kept animals of listed species to be repopulated
• the animals may not be introduced at the same time
• time period calculated forwards from the date when the first
animal was introduced
• time period during which animals intended for repopulation,
should be introduced and the process of repopulation be
completed.
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duration of measures in
the surveillance zone
(as referred to in Articles
55 and 56 of this
Regulation) Annex XI
Foot and mouth disease (FMD) 3 km 10 km 15 days 15 days 30 days
Infection with rinderpest virus (RP) 3 km 10 km 21 days 9 days 30 days
Infection with Rift Valley fever virus
(RVFV)
20 km 50 km 30 days 15 days 45 days
Infection with lumpy skin disease virus
(LSD)
20 km 50 km 28 days 17 days 45 days
Infection with Mycoplasma mycoides
subsp. mycoides SC (Contagious bovine
pleuropneumonia) (CBPP)
Establishment 3 km 45 days Not applicable 45 days
Sheep pox and goat pox (SPGP) 3 km 10 km 21 days 9 days 30 days
Infection with peste des petits ruminant
virus (PPR)
3 km 10 km 21 days 9 days 30 days
Contagious caprine pleuropneumonia
(CCPP)
Establishment 3 km 45 days Not applicable 45 days
African horse sickness (AHS) 100 km 150 km 12 months Not applicable 12 months
Infection with Burkholderia mallei
(Glanders)
Establishment Establishment 6 months Not applicable Not applicable
Classical swine fever (CSF) 3 km 10 km 15 days 15 days 30 days
African swine fever (ASF) 3 km 10 km 15 days 15 days 30 days
Highly pathogenic avian influenza (HPAI) 3 km 10 km 21 day 9 days 30 days
Infection with Newcastle disease virus
(NCD)
3 km 10 km 21 days 9 days 30 days
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Annex F – Uncertainty
Source or location
of the uncertainty
# Nature or cause of uncertainty as described by the experts Impact of the uncertainty on the assessment
ToR 1 1 There is limited data on the performance of the diagnostic tests
considered in the assessment, particularly regarding the sensitivity
and specificity of clinical examination, in the different species.
The effectiveness of the sampling strategies could be over or
underestimated.
ToR 2 and ToR3 2 Information on the period elapsed between the earliest point of
infection and the suspicion report could only be retrieved from one
reference for swine, and two references for small ruminants (one
for sheep and one for goats).
The effectiveness of the proposed monitoring period based on the limited
available evidence, could be overestimated if infection affected species in
which clinical signs are less evident (sheep, goats).
3 Most references retrieved presented data from outbreaks occurring
in 2001 and 2007, and in one country (UK), and therefore, data
may not be representative for other regions/periods due to
differences in production systems affecting the effectiveness of
surveillance systems.
The effectiveness of the proposed monitoring period could be over or
underestimated.
4 Kernels are based on analyses of epidemics involving strains of
serotype O. The efficiency of transmission routes may differ for
other serotypes/strains (e.g. airborne spread; survival on fomites)
changing the shape of the kernel.
The effectiveness of the proposed zone size could be over or
underestimated.
5 Kernels used in this assessment are based on the analyses of four
epidemics in northern Europe (UK and NL) and one in Japan. The
efficiency of different transmission routes is likely to vary with
environmental conditions (e.g. temperature and relative humidity)
and with farming practices, which may influence the shape of the
kernel.
The effectiveness of the proposed zone size could be over or
underestimated.
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